The Journal of the American Diabetes Association


diabetes

Volume 15 • 1966

INDEX


3-13-67

By Subject and Author



153687

Copyright 1967, by American Diabetes Association, Inc.



DIABETES®

The Journal of the American Diabetes Association

EDITOR, IRVING GRAEF, M.D., New York

ASSOCIATE EDITORS: HARVEY C. KNOWLES, JR., M.D., Cincinnati • DAVID M. KIPNIS, M.D., St. Louis ADVISORY EDITORS: CHARLES H. BEST, M.D., Toronto . FRANK N. ALLAN, M.D., Boston

ABSTRACTS EDITOR, WILLIAM R. KIRTLEY, M.D., Indianapolis . MANAGING EDITOR, EDWARD W. SANDERSON, New York ART EDITOR, W. I. VAN DER POEL, New York

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1966 THADDEUS S. DANOWSKI, M.D., Pittsburgh C. F. GASTINEAU, M.D., Rochester, Minn. SYDNEY S. GELLIS, M.D., Boston DAVID M. KIPNIS, M.D., St. Louis PAUL E. LACY, M.D., St. Louis HERBERT H. MARKS, New York MARVIN D. SIPERSTEIN, M.D., Ph.D., Dallas

GERALD A. WRENSHALL, Ph.D., Toronto

TERM EXPIRING DECEMBER 1966 SAMUEL B. BEASER, M.D., Boston ARTHUR R. COLWELL, JR., M.D., Wilmette, Ill.

HIROMICHI T. NARAHARA, M.D., St.

OTAKAR V. SIREK, M.D., PH.D., Toronto ELEANOR A. WASKOW, M.D., Phoenix PETER H. WRIGHT, M.D., Indianapolis

TERM EXPIRING DECEMBER 1967 SOLOMON A. BERSON, M.D., New York STEFAN S. FAJANS, M.D., Ann Arbor PETER H. FORSHAM, M.D., San Francisco GEROLD M. GRODSKY, PH.D., San Fran-

PHILIP M. LECOMPTE, M.D., Boston IRVING H. LEOPOLD, M.D., New York MAX MILLER, M.D., Cleveland HERBERT POLLACK, M.D., Leesburg, Va.

TERM EXPIRING DECEMBER 1967 JOSEPH D. BROWN, M.D., Iowa City MARIA G. BUSE, M.D., Charleston, S.C. PAUL S. ENTMACHER, M.D., New York JOHN A. GALLOWAY, M.D., Indianapolis BERT F. KELTZ, M.D., Oklahoma City CHARLES R. SHUMAN, M.D., Philadelphia

TERM EXPIRING DECEMBER 1968 JAMES ASHMORE, PH.D., Indianapolis FREDERICK C. GOETZ, M.D., Minneapolis CHRISTIAN R. KLIMT, M.D., DR. P.H., Baltimore ARNOLD LAZAROW, M.D., Ph.D., Minne-

abolis ALEXANDER MARBLE, M.D., New York ALEXANDER MARBLE, M.D., Boston HENRY T. RICKETTS, M.D., Chicago THEODORE B. VAN ITALLIE, M.D., New

TERM EXPIRING DECEMBER 1968 BURIS R. BOSHELL, M.D., Birmingham, Ala.

WAYNE V. GREENBERG, M.D., Augusta. Ga.

RONALD K. KALKHOFF, M.D., Milwaukee CHARLES A. ROSENBERG, M.D., Washington, D.C.

THOMAS G. SKILLMAN, M.D., Omaha LEON S. SMELO, M.D., Birmingham, Ala.

The Editors, members of the Editorial Board, and Abstractors listed above served in these capacities as of December 31, 1966.

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and re-lated fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted. Permission to reproduce all or part of papers appearing in it may be granted on application, under appropriate conditions and if proper credit is given. Such permission should be requested by written application to the Secretary of the Association.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association.

The Editors will be pleased to consider

for publication papers presented at the Annual Meeting of the American Diabetes Association.

Manuscript Specifications: The length of manuscripts (not including special articles or lectures) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation may be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing and, if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style illustrated by the following examples:

For Periodicals-Banting, F. G., and Best, C. H.: The internal secretion of the pan-creas. J. Lab. Clin. Med. 7:251-66, Feb.

Subscription and Advertising Information American Union, \$14.00 per year; elsewhere, \$16.00 per year. Individual copies available at

Medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: \$7.00 per year.

Co. spondence concerning subscriptions should addressed to the Subscription Department, DIABLIES. Checks, money orders and drafts for

For Books-Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. If possible, this should be self-contained and understandable without reference to the text.

Photographs, drawings and figures should be suitable for reproduction purposes. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial corre-spondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertising and the right to cancel any advertising contracts. ing contract.

DIABETES: The Journal of the American Diabetes
Association is published every month by the
Association at 18 East 48th Street, New York,
New York 10017. Entire contents copyright 1967
by the American Diabetes Association, Inc.; all
rights reserved. SECOND CLASS POSTAGE PAID AT
NEW YORK, N.Y.
Members receive the Journal as part of their
membership privileges. The annual subscription
rates for nonmembers are as follows: United
States, U. S. Possessions, Canada and the Pan-

Bo

Reviewers

The Editors of DIABETES: The Journal of the American Diabetes Association, are grateful to the following persons who, although not members of the Editorial Board, evaluated scientific contributions to the Journal, or reviewed books during the year 1966.

MANUSCRIPTS

Margaret J. Albrink, M.D., Morgantown, West Va. Reubin Andres, M.D., Baltimore Ronald A. Arky, M.D., Boston Earl S. Barker, M.D., Philadelphia James Bastron, M.D., Rochester, Minn. Bernard Becker, M.D., St. Louis Edwin L. Bierman, M.D., Seattle Buris R. Boshell, M.D., Birmingham, Ala. Donald K. Briggs, M.D., New York Peter M. Burkholder, M.D., Durham, N.C. Maria G. Buse, M.D., Charleston, S.C. George C. Cahill, Jr., M.D., Boston Bernice Cohen, Ph.D., Baltimore John A. Colwell, M.D., Chicago Marvin Cornblath, M.D., Chicago James W. Craig, M.D., Cleveland John K. Davidson, M.D., Ph.D., Toronto Norman Deane, M.D., New York G. H. Dixon, Ph.D., Vancouver William E. Dulin, Ph.D., Kalamazoo John Dupre, B.M., Montreal John W. Ensinck, M.D., Seattle Donnell E. Etzwiler, M.D., Minneapolis Saul Farber, M.D., New York James B. Field, M.D., Pittsburgh Richard A. Field, M.D., Philadelphia John C. Floyd, Jr., M.D., Ann Arbor Piero P. Foa, M.D., Detroit Noble O. Fowler, M.D., Cincinnati Norbert Freinkel, M.D., Chicago Gordon E. Gibbs, Ph.D., M.D., Omaha Martin G. Goldner, M.D., Brooklyn Charles J. Goodner, M.D., Seattle John W. Greene, Jr., M.D., Lexington, Ky. David E. Haft, M.D., New York Kurt Hirschhorn, M.D., New York Eugene A. Johnson, Ph.D., Minneapolis Martin H. Kalser, M.D., Miami Laurance W. Kinsell, M.D., Oakland, Calif. William R. Kirtley, M.D., Indianapolis Leo P. Krall, M.D., Boston Simon I. Zacks, M.D., Philadelphia

Ann M. Lawrence, M.D., Chicago Jack R. Leonards, M.D., Cleveland Lena Lewis, Ph.D., Cleveland Simeon Locke, M.D., Boston Mary R. Loveless, M.D., Westport, Conn. Leonard L. Madison, M.D., Dallas Peter H. Moloney, Ph.D., Toronto Carl R. Morgan, Ph.D., Indianapolis Hiromichi T. Narahara, M.D., St. Louis Charles R. Park, M.D., Nashville, Tenn. James M. Pickens, M.D., Columbia, Mo. Victor E. Pollak, M.D., Chicago Daniel Porte, Jr., M.D., Seattle Thaddeus E. Prout, M.D., Baltimore David Rabinowitz, M.D., Baltimore Gerald Reaven, M.D., Palo Alto Lillian Recant, M.D., Washington, D.C. Mary Root, Ph.D., Indianapolis Nagueb Samaan, M.D., Ph.D., Cleveland Donald Schalch, M.D., Rochester, N.Y. Theodore B. Schwartz, M.D., Chicago Holbrooke S. Seltzer, M.D., Dallas Joseph C. Shipp, M.D., Gainesville, Fla. Otakar V. Sirek, M.D., Ph.D., Toronto Thomas G. Skillman, M.D., Omaha J. Stuart Soeldner, M.D., Boston Robert G. Spiro, M.D., Boston Randall G. Sprague, M.D., Rochester, Minn. Jurgen Steinke, M.D., Boston Roger H. Unger, M.D., Dallas Bruno W. Volk, M.D., Brooklyn Mladen Vranic, M.D., Toronto Leo Waitzkin, M.D., Brockton, Mass. William B. Weil, M.D., Gainesville, Fla. George G. Welsh, III, M.D., Burlington, Vt. Kelly M. West, M.D., Oklahoma City Priscilla White, M.D., Boston Robert H. Williams, M.D., Seattle Albert I. Winegrad, M.D., Philadelphia Ira G. Wool, M.D., Chicago Peter H. Wright, M.D., Indianapolis

Books

Stanley S. Bergen, M.D., New York Robert F. Bradley, M.D., Boston Max Ellenberg, M.D., New York

4

A

A

A

AC AC

AC

This index covers all reading matter in Volume 15 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 31.

A

ABDOMEN and glycogen storage disease, 407 leiomyosarcoma and hypoglycemia, *701 lymph, insulin-like activity, *294 pain and hyperlipemia, 566 and pancreatic A-cell tumor, 709

ABORTIONS and alloxan-diabetic pregnant mice, 199-203

ACANTHOSIS NIGRICANS, *69

ACETATE and lipogenesis, °533-534 metabolism and obese rats, °611 thiokinase, °533-534, 694

ACETATE-1-C-14 incorporation and alloxan diabetes, 473

ACETOACETATES and insulin secretion and hypoglycemia, 811

ACETOHEXAMIDE and free fatty acids and blood glucose, 315-318 and hypoglycemia, 362-364 and butazolidine, °520-521

ACETONURIA and spontaneous diabetes, 327 and sulfated insulin, 459

ACETYLCARBOXYLASE and fatty acid synthesis, 448-449

ACHARD-THIERS-SYNDROME, *436 ACHILLES REFLEX, *435-436, 507

ACIDOSIS, DIABETIC and benzolsulfonamidodiazine, *531 and hypokalemia, *843 and lactate metabolism, 423-429 and potassium replacement study, 694-

and pregnancy, 73, *542 in pre-insulin era, 277 and syrupy blood, 760-761

ACIDOSIS, METABOLIC and diabetes, *369 and xylitol, *140 ACIDS

acetylsalicylic and complement in diabetes, 730-733

amino isobutyric and 2-deoxyglucose, *701 transport, 120, 373-374 ascorbic

ascorbic and carbohydrate metabolism, *228 beta-hydroxybutyric

and glycerol release, *433 deoxyribose nucleic and glucose metabolism, *365 ethacrynic, *550 lactic

and insulin, *764 and serum albumin, 389 nicotinic

and adipose tissue metabolism, *64 and epinephrine, 630 and free fatty acids, *914 and lipolysis, 633 phosphomolybdic and blood glucose determinations,

polysaccharides and atherosclerosis and diabetes, *537

uric

and ketoacidosis, 357-358 and phenformin, *544-545

ACROMEGALY, 355 in forearm skin capillaries study, 251, 253

and growth hormone and assay, *540 excess, 504 and insulin, *365 and irradiation, *367 and hyperostosis of spine, *916 and insulin, 30, *69

ACTH. See Adrenocorticotrophic hor-

ACTINOMYCIN D, 377 and adenine incorporation into RNA, *848

and glucokinase, *545 and growth hormone, *136 and RNA synthesis, 641

ADDISON'S DISEASE and diabetes, *70, *549

ADENINE incorporation into RNA, *848

ADENOHYPOPHYSES and growth hormone, 30 polypeptide, *702

3,5-ADENOSINE MONOPHOSPHATE and glucaseun, 188 and glucose uptake, 636 and hormones, 633 and insulin, *433, 630 and lipolysis, *765 and metabolism, 641-642

ADENOSINE TRIPHOSPHATE induction and glucose, insulin and glucagon, *917 and insulin secretion, 630

ADRENAL GLANDS ablation and retinopathy, 133 and carbohydrate tolerance, *226 carcinoma

and hypoglycemia, *769 and diabetes with Sheehan's syndrome, 75 and diazoxide-induced hyperglycemia, *295

function

and diabetes regulation, *291 in thyrotoxicosis, *916 in hyperadrenocorticism, 24-29 hypoplasia and diabetes, *70 and hypothalamic obesity, 465, 491 insufficiency and diabetes, *549 lesions, *913 and protein-calorie deficiency, 78

ADRENALECTOMY
and blood pyruvate, *366-367
and "bound" insulin study, *843-844
and diabetes, *609
and diazoxide-induced hyperglycemia,
*295
and fatty acid incorporation, *916
and gluconeogenesis, *226
and pancreatectomy, 373

ADRENALIN
and blood flow, *229
and diabetes onset, *137
and insulin-like activity, *139
and insulin release, *536
and lipolysis, *764
tolerance
and protein-calorie deficiency, 80,
82-83

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

ADRENERGIC BLOCKING AGENTS, 345-349

ADRENOCORTICOSTEROIDS and hypoglycemia, 307

ADRENOCORTICOTROPHIC HOR-MONE and 3',5'-AMP, 633, 642 and diabetes, *609 and fatty acid release, 347 and gluconeogenesis, 501 and 17-hydroxycorticosteroid excretion,

319 and hyperadrenocorticism, 24 immunologic studies, *136 and insulin, *140, *521, 642

and lipolysis
and calcium, *841-842
and muscle permeability to sugar, *516
and phospholipase C, 635
and protein-calorie deficiency, 84

AGE

and blood sugar levels, °370 and carbohydrate tolerance, 168 and chromium effect on glucose toler-ance, °539-540 complement levels in diabetes, 730-733 and

cortisone glucose tolerance test, *539

and diabetes incidence, 11, 13, 14, 15, 160-163, °366 and diabetes onset, 419 and diabetic lesions, °434 and diabetic mortality, °228, °365-

366

and diabetic pregnancy, 726, 830 and diet-induced diabetes, 113 glucose tolerance and serum im-munoreactive insulin, *845 glucose tolerance tests, *438

glucose tolerance tests, °438 glycemia study, °535 growth hormone levels, °540 hemochromatosis, °513 and and and hypothyroidism and diabetes, *68-

69 and insulin action in rat adipose tissue, 430-431

and insulin

response, *226, 627 secretion, 571 and kidney lesions in alloxan diabetic rats, *437

and lipid response to carbohydrates, *137-138, *765 and liver glycogenesis, *703 and neuropathy, *368

old and islets of Langerhans, 483-485

of patients

and amputation, *293 in diabetes survey, 164 and potassium, *768

in sulfonylureas study, 270, 272 and peripheral neuropathy in juvenile diabetics, 412, 413

and retinopathy, 497-498, *548 and skin capillaries changes, 253

of subjects in blood vessel study, 234, 243, 247, 249

in caloric intake study, 893 in diabetes surveys, 97, 172 in insulin-binding study, 276 and sucrose intolerance, *369 and sulfonylureas and hypoglycemia,

363 and tolbutamide and glucose tolerance tests, 217-218

L-ALANINE-C-14 and glucagon study, 189-190
-incorporation into blood glucose, *226

ALBUMIN

and glucose metabolism, 388-398 uptake, *540-541, *542-543 and insulin adsorption, *439 antagonism, 373-378, 380-386, 835-837

inhibition, *609 and lipolysis, *842

ALCOHOL.

and gluconeogenic regulation, *526 and heart and liver disease, 570, 578 and hypoglycemia, 1 and sulfonylureas, 273

ALCOHOLISM and hypoglycemia, *70

ALDOSTERONISM, 642-643 and carbohydrate metabolism, *226

ALKALINE PHOSPHATASE, *135 liver function tests, 2

ALLERGIES to insulin, 790-796

ALLOXAN DIABETES and antibody response, *514

and aortic atherosclerosis, *537 and cerebrospinal fluid changes, 473-

and cholesterol flux into aorta, 604-608 and citrate metabolism, *845

and fatty acids

incorporation, *916 synthesis, 448-449 and glomerulosclerosis in monkey, 258-261

and gluconeogenesis in rats, 19-22 and glycogenolysis in spayed rat uteri, *437-438

and hyperlipemia, 675-678 and insulin withdrawal, 346-347 and kidney lesions in rats, *437

and lactate metabolism, 423-429 and lipogenic defect in rabbits, *533-534

and liver glucokinase, *545 metabolism and insulin, *767

and metabolism studies in rats, 451-455

and neonatal pancreas homografts in

golden hamsters, 51-57
and nerve metabolism, 696-698
and nialamide, 686-689
and pancreas beta-cell changes, *549
in pregnant mice, 194-203
and pyruvate-3-C-14 and L-alanine-C-

14 incorporation into blood glucose, \$226 glucose, *2 and thiazides, *140

and tricarboxylic acid cycle metabo-lism, *844

ALPHA-KETOGLUTARATE and glucose formation, 19

AMERICAN DIABETES ASSOCIATION

merican Diabertes Association annual meetings abstracts, 512-551, 554, 705

Twenty-seventh, 371, 440, 552, 618, 705, 773, 850-851, 819-820

Twenty-sixth, 71, 141, 230, 296-301, 371, 440, 552, 612

awards

Banting Medals, 612 Lilly, 553, 613, 707, 773-774 British Diabetic Association meeting,

72 on Affiliate Associations, Committee

852

Committee on Bequests, 852 Committee on Charles H. Best Birthplace, 852
Committee on Emergency Medical
Care, 851

Committee on Employment and In-

surance, 851
Committee on Food and Nutrition, 851 Committee on Functions and Structure, 852

Committee on Information for Diabetics, 851
Committee on Policies, 852

Committee on Professional Education, 851

Committee on Public Education and Detection, 852

Committee on Research, 852 Committee on Scientific Awards, 851 Committee on Scientific Programs, 851 Committee on Scientific Publications, 851

Committee of State Coordinators, 852 Committee on Statistics, 851 Committee on the Use of Therapeutic

Agents, 851
Constitutional Committees, 851
Diabetes Week, 371, 441, 622, 707
Executive Committee, 851

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 October, 709-774 June, 373-442 July, 443-554 November, 775-854 March, 143-232 December, 855-920 April, 233-302 August, 555-622

fifth research symposium, 371, 440-441, 552, 619-620 film on coma, 440, 622 FORECAST
"On Brittle Diabetes," 141
"The Diabetic Looks at His Feet,"

"Oral Compounds for Diabetes," 302
"Skin Troubles and Diabetes," 618
"Your Child Can Live with Diabetes," 442
Forty-seventh Annual Session of American College of Physicians,

232

International Congress of Genetics, 232 International Diabetes Federation Sixth Congress, 72, 554

change in editors, 913 index, 72, 141 membership for physicians in training,

622 Physicians in training, necrology, 142, 232, 302, 372, 442, 554, 708, 854, 920 new ADA identification card, 618, 773 new members, 72, 141, 231, 372, 442, 707-708, 774, 920 news of Affiliate Associations, 142, 232, 302, 372, 442, 708, 853 news notes, 72, 141, 232, 302, 372, 442, 554, 622, 708, 774, 853, 920 Nominating Committee Com

Nominating Committee, 851

obituaries
Burger, Dr. Max, 699-700
Hennes, Allen R., 133-134
personals, 142, 372, 554, 853-854
postgraduate courses, 230-231, 302, 371, 441, 552-554, 618, 770-773, 850, 919
Research and Development Award Program, 621-622
Research and Development Awards, 301-302, 441-442, 553
Research and Essay Contests, 620-621. obituaries

Research and Essay Contests, 620-621, 706-707, 774, 853

research support program, 706 research symposium registration, 852

AMINO ACIDS

ıs,

h-

al

n-

re.

ia-

n,

nd

51

ns,

2

tic

and glucose tolerance tests, *544 and growth hormone, *67, 905-909 incorporation into insulin, *549-550

into protein, 377 and insulin, 5-7, *139, 560-564, 624, metabolica

metabolism and insulin, *294 nitrogen

and protein ingestion, 304, 306 penetration into squid axon, and serum insulin and growth hormone response, *917

utilization and phenethylbiguanide, *764 D-AMPICILLIN, *535

AMPUTATION, *525 of feet, *543 and vascular lesions, *68

AMYLASE digestibility study, 679, 690

ANDROGENS and diabetic impotency, *537

ANGINA PECTORIS and hyperglycemia, *137

ANGIOPATHY and Achard-Thiers syndrome, °436 and diabetic neuropathy, °228 and juvenile diabetics, 413, °437 and lipoatrophic diabetes, 351-355 and pedal angiography study, °525 and proteinuria study, °435

ANHYDROFORMALDEHYDE-ANILINE and insulin, *551

ANTAGONISTS. See also Antibodies to insulin albumin, 373-378, 380-386 and diabetic coma, *548 and insulin reserve, *530 response, 867

ANTIBIOTICS and acetone poisoning, 810

ANTIBODIES to growth hormone, *846 to insulin, *139

and alloxan diabetic mice, *514 and diabetes in rabbits, 579-584 and endogenous insulin secretion.

histological and autoradiographic studies, 205-211 and infants of diabetic mothers, *847

and insulin degradation, 644 and insulin immunity study, 812-820

and insulin resistance, *140, *764 and insulin study, *763 and liver insulin-like activity, *139-140

placental transfer of insulin-I-131, *768 and production in guinea pigs, 668-

674 and serum insulin study, 359-361 and sulfated insulin study, 457-465 technic for determining, *67 insulin-binding, 790-796

AORTIC LIPIDOSIS, 159, 178

ARGININE

and growth hormone, °67, °516, 907-908 infusion and diabetes, *848 and insulin response, 627

ARTERIOGRAPHY and diabetic osteopathy, *534-535

ARTERIOLONEPHROSCLEROSIS and glomerular mesangial thickening, °513

ARTERIOSCLEROSIS and diabetes, °550 and diabetic neuropathy, 63, °228 and diabetic tree shrews, 328, 329 and free fatty acids, °366 and hyperglycemia, °137 and long-standing diabetes, 278 and tumoriform focal muscular degeneration, °134

ARTHRITIS, RHEUMATOID in skin capillary study, 253

ATHEROSCLEROSIS and acid polysaccharides, *537 and aortic lipidosis, 178 and carbohydrates, 874, 888 and cholesterol, *140, 604 and diabetes, *844-845 and diabetic lesions, 114, 128 and exercise 603 and exercise, 603 and glomerular mesangial thickening, °513

and hyperemia and adrenalin study, *229 lesion structure in, 8 and neuropathy, 471 and serum B-glucuronidase, *848

AUTOANALYZER TEST, 11, 129, 206, *225, 263, 332, *522, 694,

AZOTEMIA, 363, *609 and tolbutamide and glucose tolerance tests, 215, 218

BASEMENT MEMBRANE

changes and diabetes, 233-250 and prediabetes, 880 in diabetic glomerulosclerosis, 61-63 in lipoatrophic diabetes patient, 263 study of structure, *512 thickening, *610, 648 in glomerulosclerosis study, 259 in panhypopituitary and diabetic patient, 420, 420, 420 tient, 420-422

tient, 420-422 in prediabetes, 355 in recent juvenile diabetes, *227 of skin capillaries, 254 in South African diabetics, *513 and visceral neuropathy, 93

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 September, 623-708 May, 303-372 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 April, 233-302 August, 555-622 December, 855-920

BENZOLSULFONAMIDODIAZINE,

BENZOTHIADIAZINE and insulin release, *765

BENZOTHIAZIDES and glucose uptake, "365

BICARBONATE-C-14 and glucagon study, 190-191 and hepatic gluconeogenesis, 19

BILIRUBIN and liver function tests, 2

BLADDER and diabetes, °524-525

BLINDNESS, DIABETIC, *294

BLOOD amino acids and 2-deoxyglucose, *701 and glucagon, 188 catecholamines

and diazoxide-induced hyperglyce-

mia, *295 ow and adrenalin, *229 and chelating agents, 45-46 and diabetes, 323-326, *370 forearm, *544 and insulin secretion study, *521 and secretin, *768 group

and fetal loss in diabetic pregnan-cies, *436

growth hormone fetal and maternal, *295 hematocrits and diet-induced diabetes, 112

insulin and glucagon and secretin, *845-846 and growth hormone, 39

and intestinal glucose absorption, 555

and leucine, 562 and portal hyperglycemia and gas-trointestinal system, °532-533 insulin-like activity and thiazide, 321 ketones

and dichloroisoproterenol, 348 and medium-chain triglycerides, 723 and prediabetes, *519 and triglycerides, 723-724

lipids and carbohydrates, 874, 888 and dietary fat, 722, 729 and juvenile diabetes, *703-704 and lipoatrophic diabetes, 264 pyruvate, *366-367

samples in alcohol study, 570, 578 in amino acid metabolism study, 5-7 in bound insulin assay, 895 of children of diabetic parents, 881-882

of Chinese hamsters, 331

in diabetes survey, 11 of diabetic tree shrews, 330

in diazoxide study, 144
in diet and diabetes study, 106
and enzyme strip blood glucose test
study, 691-694

from galactosemic patients, *844 and glucagon study, 856 and glucose assay method, *536 and glycogen reserves study, *530 in growth hormone-induced diabetes

study, 31 and hyperlipemia study, 675 in insulin antibody study, 206 in insulin-induced hypoglycemia

study, 308
in magnesium deficiency and carbohydrate metabolism study,

new technic, *611 in study of metabolism of ruminants, 326, 335 in plasma insulin study, 359

in plasma insulin study, 359
in sulfoavlurea study, 315
technic for repeated, 759
in tolbutamide study, 91
of tree shrews with spontaneous diabetes, 327-328
syrupy, 760-761

tests and diabetes screening, *541 in glycogen storage disease, 407 urea nitrogen and retinopathy, °548

BLOOD GLUCOSE. See also Blood sugar

sugar and bound insulin study, *843-844 and 2-deoxyglucose, *434 and diabetes diagnosis, *768-769 and diabetes surveys, 11, 99, 166-169 and dichloroisoproterenol, 348 and diet in sand rats, 105 and diurnal cycle in starvation, *533 and enzymes, 475-479 in forearm skin capillary study, 251-

252

gestational and potential diabetes, 466-470 and glucagon, 855-865 and glucose loading, 1-4 and glycogen infusion, *530 homeostasis

and glucoregulatory hormones, 500-505

and insulin, 123-125 secretion, 571-578 and kwashiorkor, *225-226 and lipoatrophic diabetes, 351 and morphine, *68

and morphine, -oo and plasma, growth hormone and uri-nary catecholamines, *848 postprandial

and monoamine-oxidase inhibitors, *764

and quinethazone, *546 and rabbits immunized with insulin, 580

response

to sulfonylureas, *320 to sultonylureas, *320
and serum immunoreactive insulin
and prediabetes, *518
and siblings of diabetic children, 401402
and smoking, *849
and sulfated insulin study, 457-465
and sulfonylureas, 314-318

tests.

AutoAnalyzer, 11, 129, 206, *225, 263, 332, *522, 694, 868 Dextrostix, *225, 295, *367, *541-

Dextrostix, °225, 295, °367, °541-542, 833 and diabetes detection, 212-218 and diabetes prevalence study, °528 and diabetic pregnancy, 831 enzyme strip, 691-694 and juvenile diabetes, *550-551 and plasma glucose tests, 775-777 study, *845 in sulfonylurea and L-leucine study, 223

and tolbutamide, 279-280, 597, 598 and triglycerides, 723-724

BLOOD PRESSURE and blood flow in diabetes, 326 and frusemide, *847 and hyperosmolar nonketotic diabetic coma, 714-720 in panhypopituitarism with diabetes case, 419

BLOOD SUGAR. See also Blood glucose and acetone poisoning, 810 and alcohol, \$526

and alcohol, *526 of alloxanized pregnant mice, 197-203 and arterial disease, *137 and carbohydrate intolerance study, *609

and children of diabetic parents, 882-883

BO

BO

BO

and diabetes survey, *369 and diabetics with gout, *918 and diazoxide, 143 and diet, *370 of ruminants, 335

fasting and diabetic Chinese hamsters, *534 and retinopathy, *548 and tolbutamide, *542

in glomerulosclerosis study, 260-261 and glucagon study, 742-743, 746 and glucose tolerance test and ricemeal test reproducibility, 901-904

storage disease, 406, glycogen sto *519-520 and hyperosmolar nonketotic coma,

and 714-721 and infant hypoglycemia, *846

and insulin in severe diabetes, 219-221

insulin-induced hypoglycemia, 307-313 in juvenile diabetes study, 412 and pancreatectomy, 179-182

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142 March, 143-232 April, 233-302

May, 303-372 June, 373-442 July, 443-554 August, 555-622 September, 623-708 October, 709-774 November, 775-854 December, 855-920

and pancreatic A-cell tumor patient, 710-712 and pituitary growth hormone, *436 postprandial in diguanide-sulfonylurea therapy study, *64 in diguanide-sultonylurea therapy study, °64 and potential diabetes, °918 and prediabetes, °519 and protein-calorie deficiency, 78-88 and serum lipids and uric acid correlation study, °65 and starvation, °538, 799-804 and surgery, °66 and surgery, *66 syrupy levels, 760-761 Dextrostix, °225, °541-542 and portable monitor, °536 and spontaneous remission in early diabetes, °766 Somogyi-Nelson method, °541-542 tongue surface screening procedure, 58-60 and thiazides, °140 and tolazamide and tolbutamide, °551 tests

8

13

y,

2-

6,

a,

ia,

BLOOD VESSELS capillaries and diabetes, *367 of South African diabetics, *513 wall thickening, *434 changes in insulin-injected cows, 593 and diabetes, *293-294 and diabetes, *293-294 forearm skin capillaries and diabetes, 252-257 pancreatic, 480-489 and diabetes, 233-250

BODY fat and skinfold thickness, 725 insulin distribution, 631-632 lower extremities wer extremities and acetone poisoning, 810 amputation, *293 diabetic foot, *543 and diabetic osteopathy, *534-535 in long-standing diabetes, 278 and pedal angiography, *525

BONES and diabetic feet, *543 and diabetic osteopathy, *534-535

BOOK REVIEWS Accident Service, edited by L. W.
Plewes, 759
Annual Review of Biochemistry, edited by P. D. Boyer, 842-843
Charcot Joints, by N. Eichenholtz, 700
Diet and Live, by Joseph I. Goodman, 511

Handbook of Physiology, Section 5, Adipose Tissue, edited by Al-bert E. Renold and George F. Cahill, Jr., 224-225

Inborn Errors of Metabolism (Part I:

Inborn Errors of Metabolism (Part I: Clinical Aspects), by David Yi-Yung Hsia, 432

The Kidney in Diabetes Mellitus, by Age Chr. Thomsen, English translation by H. Cowan, 364

The Management of the Diabetic Patient, by Elaine P. Ralli, 432

Physiology and Biophysics, by Theodore C. Ruch and Harry D. Patton. 289 Patton, 289

BOWMAN'S CAPSULE and diabetic tree shrews, 328-329 and nialamide study, 688

BRAIN catecholamine catecholamine
and morphine, *68
and diabetic angiopathy, *437
and glucose dependence, 500-501
and insulin
secretion, *531
sensitivity, *844

RITRNS and hyperglycemia and diabetes, *227

BUTOXAMINE and insulin secretion, 629

C

CAFFEINE and glucose metabolism, *365

CALCIUM and citrate metabolism, *845 corticotropin-induced lipolysis, *841-842 and insulin release, 911 and lipolysis, *914

CALORIES deficiency and ketogenesis, *66 and protein deficiency, 78-88 intake in juvenile diabetes study, 411-412 and weight gain, 893, 900 in weight reduction study, 399, 405

CAPRYLATE and protein synthesis, *516-517

CARBOHYDRATES

and cataracts, *846 incorporation into serum and liver lipids, *227 in insulin response to protein study, 303 and lipids, *137-138, *368, 874, 888 of milk, *228 phospholipids, and nonphospho-lipids, *64 of postmenopausal women, *765 and syrupy blood, 760-761 utilization study, *609

in glomerular basement membrane, °512 -induced hyperlipemia and insulin response, 867 and starch and sucrose study, *433-434 and insulin secretion, 910 intolerance and diazoxide, 321 in hospital survey, 212-218 and lipid abnormalities, °843 "long-acting," °527 metabolism. See Metabolism, carbohy-

drate and new glucose tolerance test, 762 tolerance

and age, 168
and "fat-induced" hyperlipemia, 678
and hypertension and potassium deficiency, "226
and lipoatrophic diabetes, 355
and plasma nonesterified fatty acids, °766-767

and siblings of diabetic children, 404 and starvation, *527, *530 tolerance tests and simple and complex carbohy-drates, *439

CARBON-C-14 incorporation into liver glycogen and lipids, 427-429

CARBON DIOXIDE and gluconeogenesis, 19-22 and glucose, 189, 190 and lactate metabolism in alloxan-diabetic acidosis, 423, 424, 425 production and bound insulin assay, 894 in liver, 349 and urine protein, *524

CARBUTAMIDE and renal glucose reabsorption, 90, 92

CARCINOMA adrenal and hypoglycemia, *769 and carbohydrate tolerance, 218 and cryogenic hypophysectomy, *702 endometrial and carbohydrate metabolism, *913 and hypoglycemia, *436 islet cell and diazoxide, 143-148, 321 and islet cell hyperplasia, *136

CARDIOVASCULAR DISEASE. See also Heart disease atherosclerotic and diet and blood lipids, 874, 888 and diabetes and cholesterol, *512-513

CASE REPORTS. See also Case study acetone poisoning and coma and hyperglycemia, 810

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 October, 709-774 February, 73-142 June, 373-442 November, 775-854 March, 143-232 July, 443-554 April, 233-302 August, 555-622 December, 855-920

adrenal carcinoma and hypoglycemia, *769 benzolsulfonamidodiazine therapy, *531 blind diabetics, *365 calorie intake and weight gain, 893, 900 carbohydrate-induced hyperlipemia,

**433-434*

children of diabetic parents, 881-886
congenital lipodystrophic diabetes with acanthosis nigricans, diabetes and anterior pituitary insufficiency, 73-77 and gout, *918 and gout, *918
diabetic acidosis and potassium replacement study, 694-695
diabetic coma with severe insulin resistance, *548
diabetic feet, *548 diabetic glomerulosclerosis with chron-ic pancreatitis, *703 ic pancreatitis, *703 diabetic osteopathy, *534-535 diabetic pregnancies, 831-834 diabetic visceral neuropathy, 93-96 diazoxide administration in Von Gierke's disease, 406-408 diazoxide-induced diabetes in hypopituitary dwarf, 319-320 diet and lipid metabolism, °702 dibbenylbydantoin intovication and hypopituse of the control diphenylhydantoin intoxication and hyperglycemia, *916 and glucose loading studies, 780-786 glucose tolerance tests, *438 growth hormone hypersecretion, *844 hepatomegaly, *293 hyperglycemic nonketotic coma, °65 hyperosmolar nonketotic diabetic co-ma, 714-720 hypertension and frusemide therapy, *847 hypoglycemia and acetohexamide, 362-363 hypoglycemia and sulfonylureas, °320 hypophysectomy and diabetic preg-nancy, *542 hypoxia in pregnant women and glu-cose tolerance tests, 130-132 infant hypoglycemia and diarrhea, *846 insulin response to glucose, *704 insulin secretion and starvation, 799-804 islet cell carcinoma and diazoxide, 143-148 juvenile diabetics adjustment and control study, \$538-539 dwarfism, hyperlipemia and hypo-gonadism, *917 lipoatrophic diabetes, 351-353 lipoprotein lipase activity and diabetes, 565-568 long-standing diabetes mellitus, 277necrobiosis lipoidica, °611

oral and intravenous glucose tolerance tests in pregnancy, °433 pancreatic A-cell tumor and diabetes, 709-710 pancreatic islet cell adenoma with triad ad diarrhea, nypokalenna and hyperglycemia, *847 parotitis in diabetes, *367 phenformin therapy, *610-611 pituitary gland ablation, *367 plasma insulin responses to insulin and tolbutamide, 868-871 reactive Regular and Crystalline insulin in severe diabetes, 219-222
retinal artery pressure in retinopathy,

*702 subcutaneous lipomas, 807-809 sulfated insulin in insulin-resistant diabetes, 457-462 sulfonylurea therapy, *69 tongue surface test for diabetes, 59-60 tree shrews with spontaneous diabe-tes, 328-329 triamcinolone glucose tolerance test and oral hypoglycemic agents, 726-728 uric acid excretion in ketoacidosis, 357vascular complications in panhypopi-tuitarism with diabetes, 419-421 Von Gierke's disease and diazoxide therapy, *841 CASE STUDY. See also Case report lipoatrophic diabetes, 262-267 CATARACTS in alloxan-diabetic monkeys, 260 and diabetes, *846 and diabetic neuropathy, 95 and diabetic tree shrews, 329 and diet-induced diabetes, 106, 108, and Sheehan's syndrome study, 77 and tree shrews with spontaneous diabetes, 327 CATECHOLAMINES and 3',5'-AMP, 641-642 and diazoxide, 321, 630 and diazoxide-induced hyperglycemia, 409 and fatty acid metabolism, *292 and glycogenolysis, 637 and hypoglycemia, 307 ketosis, °526 and and lipolysis, 633 and morphine, *68 release and glucagon, 857 CATIONS and insulin release, 910-912 CEREBROSPINAL FLUID

lipids in diabetes, 471-474 CESAREAN SECTION, *542 and abnormal glucose tolerance tests, *525 and diabetic pregnancy, 831 diarrhea, hypokalemia CHARCOT JOINTS, *534, *543 CHELATING AGENTS and insulin release, 630 CHEROKEE INDIANS and glucose tolerance, *439 hypoglycemia and glucose CHILDREN and atherosclerotic lesions, 8 body fat and skinfold thickness, 725 and carbohydrate metabolism in kwashiorkor, *225-226 with congenital cardiac disease and growth failure, 470, 496 diabetic and insulin-binding index, 276-277 and insumi-binding index, 276-217 and synalbumin antagonist in sib-lings, 400-404 of diabetic parents, *436 and prediabetes study, 881-887 and premaneres study, 881-887 and tolbutamide, 602 and high-fat diet, *65 and hypoglycemia, *703 and pancreatic resection, *138 and parotid gland enlargement, °769 hypopituitary dwarf with diazoxide-induced diabetes, 319-322 and idiopathic hypoglycemia, synalbumin insulin antagonism, and diabetes, °546-547 and sucrose intolerance, °368-369 and urine insulin excretion study, °848 CHLOROTHIAZIDE compared with frusemide, *847 and edema, 73 and glucose uptake, *365 CHLORPROMAZINE, 102 CHLORPROPAMIDE in four-year clinical study, 269-275 and hypoglycemia, 362-364 and insulin release, 630 and insulinogenesis, 627 and L-leucine, 222-223, 560-564 and L-leucine, 222-223, long-term therapy, °135 -metformin therapy, °64 and subclinical diabetes, and thyroid function, °67 CHLORTHALIDONE, *550 and blood glucose, *546 CHOLESTEROL aortic

and alloxan diabetes, 604-608 and aortic lipidosis, 178 in cerebrospinal fluid of diabetics and nondiabetics, 472-473 and corn oil, 829 crystallization and glucose, *140

C

CI

CF

CF

CI'

CY

CO

CO

COL

COL

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

free fructose in, *918

September, 623-708 January, 1-72 May, 303-372 February, 73-142 June, 373-442 October, 709-774 March, 143-232 November, 775-854 July, 443-554 April, 233-302 August, 555-622 December, 855-920

and diet, *368 and ethyl chlorphenoxyisobutyrate, *64 and glucagon, 746 and growth hormone, *517 and insulin resistance, *226 and phenformin, *544-545, *611

CHOLINE and insulin response, *702

CHROMATOGRAPHY
column
and urine insulin-like activity, *524
of diabetic serum
and insulin sensitivity study, 792794

of fluoresceinthiocarbamyl insulins, •523 gas-liquid

and expired air study, 777, 789 and kidney carbohydrates, °517 and nonsuppressible insulin-like activity, 647 paper, 184

in alloxan diabetic acidosis study, 426-427 and glucose loading study, 779

CHROMIUM and glucose metabolism, *368 and insulin action, 649

CHROMOSOMES of diabetics, *765

CHYMOTRYPSIN, 636 insulin-like effect, 342-345

CITRATE and diabetes, *844 and insulin deficiency, 452 metabolism, *845 and synalbumin antagonist, 394-395

CLINISTIX, °529

18

nd

CYCLAMATES, 23

and acetone, 810-811
and burns, *227
and diphenylhydantoin intoxication,
*916
hyperglycemic nonketotic, *65

COMA, DIABETIC hyperosmolar nonketotic, 714-721 and insulin resistance, °548 without ketoacidosis, °137 and mannitol, °435 with Sheehan's syndrome, 75

CONGENITAL DEFECTS and maternal diabetes, 834

CONGENITAL LIPODYSTROPHIC DI-ABETES, *69

CONVULSIONS and juvenile diabetes, *847-848

CORONARY DISEASE. See Heart disease

CORTICOSTEROIDS and diabetes, *549 and gluconeogenesis, 501 and glucose metabolism, *434 and insulin action, 642-643

CORTICOTROPHIN and carbohydrate and lipid metabolism, *70 and hypoglycemia, *70

CORTISOL
and amino acid metabolism, 7
and gluconeogenesis, 19-22
and hypoglycemia, 5
and ketosis, *526
release
and burns, *227

CORTISONE
and diabetes with Sheehan's syndrome,
73
and diabetic pregnancy, °542
and fatty acid incorporation, °916
-glucose tolerance test, °228
and age, °539
and children of diabetic parents,
881

and necrobiosis lipoidica, *368 and prediabetes, *518-519 and pancreatic homografts in hamsters, 53-57 and protein-calorie deficiency study, 85

CRANIOPHARYNGIOMA, 419

CREATININE and hypoglycemia, 363

CUSHING'S SYNDROME, 355 and carbohydrate metabolism, 24-29 and growth hormone, 505

CYSTEINE and insulin inactivation, *515

D

DEFEROXAMINE TEST, *369

DELALUTIN, *913-914

2-DEOXYGLUCOSE and gluconeogenesis studies, °701 and magnesium deficiency, 737 and pituitary growth hormone, °436

DEOXYRIBOSE NUCLEIC ACID. See

DEXAMETHASONE and growth hormone, *701 and insulin secretion, 868, 873 and lipolysis and metabolism, *135-136 DEXTROSTIX, *225, *367, *541-542, 833

DIABETES MELLITUS
and Achard-Thiers syndrome, °436
and Achilles reflex, °435-436
and acid polysaccharides of aortic intima, °537
and Addison's disease, °70, °549
and adrenalin study, °137, °229
adult-onset
and benzolsulfonamidodiazine, °531
and glycodiazine, °530-531
and amino acids, 5-7, °544
and anterior pituitary insufficiency, 7377
and anti-insulin antibodies, °67
and atherosclerosis, °844-845
and basement membrane thickening,
°610, 648
and bladder, °524-525

and blepharoptosis, *226-227 and blindness, *365 and blood flow in skeletal muscle, 323-326 and blood glucose tests, 691-694

and blood glucose tests, 691-694 and blood vessel changes, 233-250, *293-294 and blood viscosity *370

and blood viscosity, *370 and burns, *227 and capillary changes, 251-257, *367 and carbohydrate and lipid metabolism and xylitol, *140 and carbohydrate metabolism, *918

and cardiovascular lesions and cholesterol, °512-513 case report

long-standing, 277-278
and cataracts, °846
and cerebrospinal fluid lipids, 471-474
"chemical"
and phenformin, °544-545
in Chinese hamsters, °523-524, °534
and chlorpropamide, °135, °228-229
and chromium deficiency, °368
and chromosome study, °765
and citrate metabolism, °845

and pregnancy, *532 and complement levels, 730-733 control, 219-221 and adrenal function and plasma insulin activity. *291

classification

sulin activity, °291 and phenformin, °610-611 and retinopathy, 497-499 and vascular disease, °292-293 and deferoxamine test, °369

and dereroxamine test, "309 detection, 212-218 and Dextrostix, "541-542 and electrocardiogram study, "550 tongue surface test screening, 58-60

and diabetic acidosis, 694-696 diagnosis, °768-769 and plasma glucose and blood glucose tests, 775-777 and starvation, °538

DIABETES: VOLUME 15 (1966) Page NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

and diarrhea, 93-96 and diazoxide, 144-145 diazoxide-induced in hypopituitary dwarf, 319-322 and diet, *917 diet-induced in sand rats, 105-113 and Dupuytren's contracture, *547 and dwarfism, hyperlipemia, and hypogonadism, *917 early and spontaneous remissions, *766 and early diagnosis, *436 etiology, *915 and evanescent parotitis, *367 and exchangeable potassium, *768 and exercise, 838-840 and feet, *543 and free fatty acid metabolism, 314-318 and glomerulosclerosis, 61-63, °434 in Chinese hamster, °547 and pancreatitis, °703 and gluconeogenesis, 19-22 and glucose and free fatty acids transfer, *609 homeostasis, *69-70 homeostasis, *69 infusions, *515 loading, 778-788 tolerance test and rice-meal test re-producibility, 901-904 and glycodiazine, °140 and gonadal function, °291, °537 and gout, *918 and growth hormone, 30-42, *610, 905-909 growth-onset and mortality, *228 and hepatomegaly, *293 and heredity, *70, 400-404 and hormones, 642-643 hydrocortisone-induced, *436 and hyperlipemia, 675-678 and hypercsmolar nonketotic coma, 714-720 and hyperostosis of spine, *916 and hyperthyroidism. *548 and hyperthyroidism, *548 and hypoglycemia, 307-313 and hypo-responsiveness to insulin, *544 and hypothyroidism, *67 and immunization with insulin in rab-bits, 579-584 and impotency and autonomic nervous system, *537-538 and gonadal function, *537 and infant hypoglycemia and synalbu-min insulin antagonism, *546-547 and infections and antibody response, *514 and insulin, *518 administration methods, *611 antagonism, 149-158, 373, 386 antibedy study, 207 immunity, 812, 819-820

and lipomas, 807-809 resistance, *140, 457-465, 649, *764 response, 286-289 to glucose and tolbutamide, 867-873 to hyperglycemia, *519 to protein, 303-306 secretion stimulation, *545-546 sensitivity, 790-796 and insulin-like activity, *69 adjustment and control, *538-539 and angiopathy, *437 and basement membrane thickening, *227 compared with diabetes with adrenal insufficiency, 76 and fats, lipids and ketones, *703-704 and forearm skin capillary changes, and insulin binding, 276-277 degradation, 643-644 production, 592 and intestinal mucosa study, 557 and intestinal nucosa study, 557 and nicotinic acid, *914 onset study, *847-848 and peripheral neuropathy, 411-418 and pyelonephritis, *610 and Regular insulin, *550-551 and ketoacidosis, 357-358 ketotic and "long-acting carbohydrate," *527 and kidney glucose, sorbitol and fruc-tose, *517 and growth hormone, *551 and tolbutamide study, *65 and lipemia, *524 and lipid synthesis, 346 and lipoprotein lipase activity, 565-569

and longevity and mortality, °67-68 management, °525-526 and portable glucose monitor, °536 maternal and congenital malformations, 194 and infant hypoglucosemia, *917 maturity-onset and aldosteronism, *226 and arginine infusion, *848

and triglycerides, 723-724 and metabolic acidosis, *369 and microangiopathy in digestive tract, *913 monoamine-oxidase *764 inhibitors. and and mortality and amputation, *293 of blind, *294

and myocardial infarction, and necrobiosis lipoidica, *368 and nervous system metabolism, 696-698

and neurogenic vesical dysfunction,

and obesity, *915-916 and congenital islet hyperplasia in mice, *435 and starvation, *527 onset

and hyperglycemic nonketotic coma, and osteopathy, *534-535 and pancreatic A-cell tumors, 709-712 panhypopituitarism

and vascular disease, 419-422 and parotid gland enlargement, *847,

and periodontal disease in Chinese hamster, *531
and peripheral glucose metabolism,
*135

and phagocytosis, *915 and phenethylbiguanide, *520, *764 and phenformin, *136

and pituitary hormones, *609 and plasma assays, *914

fatty acids and carbohydrate tolerance, *766-767

free fatty acids, *366 insulin response, 630-631 triglycerides, *843 potential

and gestational blood glucose levels, 466-470

and pregnancy, *917-918 prevalence study, *528 and Cherokee Indians, *439 prevention and nialamide, 686-689

and nialamide, 686-689 and tolbutamide, 602 prognosis, *228, *365-366 and protein-calorie deficiency, 87 and quinethazone, *546 and reactive hypoglycemia, 3 and renal failure, *138 and retinopathy, *548 screening, *366, *541 and age, *845 and follow-up, *846 and serum

DIA

a a

DIA

aı

aı

-i

DIB

DIC

DIE

atl

and serum

B-glucuronidase activity, *848 lipids, *536-537

proteins, 331-334 and sex incidence, *227-228 and skin lesions, *845 and sorbitol pathway, *918

spontaneous in tree shrews, 327-330 and starvation, 798-809 and blood glucose, in sand rat, *530

subclinical and frusemide, *847 and sulfonylureas

and L-leucine, 222-223 and metformin-chlorpropamide ther-

apy, *64 and surgery, *66 survey

and glucose, free fatty acids and insulin, *528

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142 March, 143-232 April, 233-302

May, 303-372 June, 373-442 July, 443-554 August, 555-622

September, 623-708 October, 709-774 November, 775-854 December, 855-920

and glycosuria, blood sugar and body weight, *369 in Herrenberg, Germany, *227 in Malta, *295 of mental hospitals, 97-103, 164-172 in Oxford, England, *849 of Pima Indians, *527-528 and Polynesians, *437 of recognized and unrecognized 160. of recognized and unrecognized, 160-163 of sex distribution and frequency of of sex distribution and frequency of concomitants and complications, 507-510
of South Africans and capillary changes, *513
in Uruguay, Venezuela, Malaya, and East Pakistan, 9-17
and thyroid disorders, *68-69
and tolbutamide, 90-92, 663-666 and chlorpropamide and tolbuta-mide, 269-275 with sulfonylureas, *69 and tolbutamide loading, 279-280 and triglycerides, *437 and tumoriform focal muscular degen-eration, *134 and protein synthesis, 635 and urine hydroxyproline, °134 tests, °529 and vascular lesions, °65-66, °68, °136 and zinc metabolism, °914-915 and plasma insulin levels, *227

in

na.

12

17,

ese

m,

4

er-

els,

er-

in-

DIABETES, PANCREATIC

DIARRHEA MARHEA and diabetic visceral neuropathy, 93-96 and glycodiazine, *530-531 and infant hypoglycemia, *846-847 and islet cell adenoma, *847 and lactose, *609 and sucrose intolerance, *368-369

DIAZOXIDE and glucose uptake, *365 and glycogen storage disease, 406-410 and hyperglycemia, 143-148 -induced diabetes in hypopituitary dwarf, 319-322
-induced hyperglycemia, *295
and insulin secretion, *435, *523, 630,
*765 and Von Gierke's disease, *841

DIBENAMINE, 347

DICHLOROISOPROTERENOL and epinephrine, 347-349

in aortic lipidosis study, 159, 178 and artificial sweeteners, 23 atherogenic, *537 and cardiovascular lesions, *512-513 and blood sugar, *370

carbohydrate-rich and glycogen storage disease, 406 cholesterol free and corn oil, 829 corn oil and medium-chain triglycer-ides, 723-724 and diabetes in sand rat, 330, °917 study in Uruguay, Venezuela, Ma-laya and East Pakistan, 13, 14, 15-16, 17 survey, 97, 164 and diabetic Chinese hamsters, *534 and diabetic pregnancy, 830 of dogs in growth hormone study, 31 and glucose tolerance, *438 blood lipids and ketones, *703 and hyperlipemia, 675-678 and red blood cell lipids, 722, 729 and galactose utilization, 662, 667 in glomerulosclerosis study, 258-261 and glucokinase, 477 and gluconeogenesis in rats, *226 and glucose and acetate metabolism in rats, *611 -loading study, 781 tolerance tests, 105-113, 903-904 and gout, hyperuricema and diabetes, and high-amylose corn starches, 679, 690

high-carbohydrate and serum lipids and phospholipids, and starvation ketosis, *66 high carbohydrate, low fat and serum triglycerides, 874 high fat and aortic cholesterol in alloxan dia-betes, 604, 606-607 and atheroma, 604-608 and atherosclerotic lesions, 114, 126 and carbohydrate tolerance, *766and carbohydrate tolerance, 767 and ketosis, 423-424 and plasma, lipids, glucose and ke-tones, °65 and uric acid excretion, 358

and three active exercisin, 30s high fat and high carbohydrate and hyperglycemia, 631 and hormonal release, *918 and human milk lipids, *228 and hyperlipemia, 675-678 in hypoglycemia study, 1 and insulin-induced hypoglycemia, 307, 308 and insulin secretion study, 572 and intestinal mucosa study, 556 in islet cell carcinoma and diazoxide

study, 144 in juvenile diabetes study, 411-412 in L-leucine and sulfonylurea study, 222 and lipemia, *524

protein-calorie deficient and carbohydrate metabolism, 78-88 and catalystates, *915 and obese diabetics, *915 and oral hypoglycemic agents in di-abetic pregnancy, 726-728 of ruminants in metabolism study, 326, 335 spontaneous diabetes in tree shrews, 328-329 starch and sucrose and hyperlipemia study, *433-434 and sulfated insulin study, 457 and sulfonylurea study, 314 and weight reduction, 399, 405

and lipid
metabolism, °702
response, °368
and lipoatrophic diabetes case study,
263, 264
and "long-acting carbohydrate,". °527
in long-standing diabetes, 277-278

and carbohydrate metabolism, 735-

of mice in islets of Langerhans study,

and lipid response, *765

and phenformin therapy, *136

DIETHYLSTILBOESTROL and diabetes with Sheehan's syndrome,

DIHYDROERGOTAMINE and hyperglycemia, *434

and lipid

low fat

low magnesium

738

DINITROPHENOL and glucose insulinogenesis, 626

DIPHENYLHYDANTOIN, *916

DIPHENYLTHIOCARBAZONE, 481 and pancreas islet cells, 598

DISODIUM and insulin release, 44-50

DNA and glomerular basement membrane, *512 and glucose metabolism, *365 synthesis and islets of Langerhans, 489

DUPUYTREN'S CONTRACTURE and diabetes, *547

DWARFISM in alloxan-diabetic monkeys, 261 and chorionic growth hormone-prolac-tin, *846 and family history, *917

hypopituitary and diazoxide-induced diabetes, 319and insulin release study, *516

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 April, 233-302 December, 855-920 August, 555-622

E

EAST PAKISTAN glucose tolerance, nutrition, and diabetes in, 9-17

ELECTRICAL POTENTIAL of rat adipose tissue and insulin, *291

ELECTROCARDIOGRAPHY and alcoholics, 578 in diabetes surveys, 170, °550 and diabetic acidosis and potassium replacement study, 695 and panhypopituitarism and diabetic patient, 420

ELECTROMYOGRAPHY in juvenile diabetic study, 412-417

ELECTROPHORESIS acrylamide gel disc and synalbumin antagonist, *536 and insulin immunity study, 815 and nonsuppressible insulin-like activity, 647 of pancreatic proteins and insulin, 342, 343-344 paper

of liver tissue in sulfonylurea study, 273 serum protein, 150, 151-153, 331, 332-334 starch-gel and hexokinase, *518 and insulin, 875-878 and nonsuppressible insulin-like activity, *542-543

ENDOCRINE GLANDS and carbohydrate metabolism, 78-88 and hypoglycemia, *70

and hypothalamic obesity, 465, 491 and pancreas homografts in hamsters, 51-57 **ENZYMES**

and galactose utilization, 662 and galactosemia, *844 and gluconeogenesis, 19-22 and glucose uptake, amino acid up-take, and glycogen synthesis, 636 and glycogen synthesis, 492-495 glycolytic and gluconeogenic, 638-639 inhibition and phenethylbiguanide, 173 and insulin cleavage, 282 deficiency, 451-455
-like activity, 341-345
and lipogenesis in rabbits, *533-534 and liver metabolism, 346-349 and muscle tissue, 635

synthesis and fatty acid synthesis, 448 and gluconeogenesis, *701 and gluconeogenesis, *701 and urine glucose test, 127-129

and high-fat diet, *65 and hypoglycemia, 4 **EPINEPHRINE**

and diabetes prevention, 688
excretion tests, *537-538
and fatty acids, 347, *916
and glucose response and hepatic electrolyte, *434
and glycogen storage disease, *529
and hyperadrenocorticism, 27 and hyperglycemia, 145-146, 147-148, and hypoglycemia, 5 and insulin-induced hypoglycemia, 312 describin secretion, *543, 571-577, and insulin secretion, *543, 627, 629, 643, 910 and lipids and lipolysis, *535 and lipolysis, 633 and liver electrolyte and glucose, *226 release and burns, *227 and serum insulin and insulin secretion,

ERGOTAMINE, 347 and diabetic osteopathy, *535

ERYTHROCYTES in blood vessels of skin study, 234 and diabetic tree shrews, 328 magnesium, 735

ESTRADIOL and glycogen synthetase in rat uterus, *769

ESTROGENS and glucose tolerance, *914 and growth hormone secretion, *291-292 and insulin, 630, 643

ETHANOL effect on insulin augmentation, *228

ETHIONINE and glucokinase, *545

EXERCISE

ETHYL CHLORPHENOXYISOBUTY-RATE, *64

ETHYLENEDIAMINE TETRAACE-TATE, *842 and insulin release, 44-50

and diabetes, 165 prevention, *436 and ketoacidosis, 504 and serum cholesterol, 603 and serum immunoreactive insulin, 838-840

EYE blepharoptosis, and diabetes mellitus, *226-227 in diabetes with Sheehan's syndrome, 74-75, 76 and diabetic visceral neuropathy, 94 of insulin-injected cows, 593 in lipoatrophic diabetes, 262 in panhypopituitarism with diabetes, 419, 420 contraction in retinopathy, vitreous

FAMILY HISTORY and blood vessel study, 234 and chromosome study, *765 and diabetes and Addison's disease, °70 and dwarfism, hyperlipemia, and hypogonadism, °917 hypogonadism, incidence study, 12-13 screening, 214, 216, *366 survey, 99-100, 165, 171 and forearm skin capillary study, 251, 253 and glucose tolerance tests, *438, *535, *541 and jaundice during chlorpropamide therapy, °135 in lipoatrophic diabetes, 262 and panhypopituitarism with diabetes, and phenethylbiguanide study, 173 and prediabetes, °519, 881 and synalbumin antagonist, 400-404 and urine insulin excretion, °848

FATTY ACIDS absorption and protein synthesis, 268 and diet of ruminants, 335 and dietary fat, 722 esterification and nicotinic acid, *64 free and arginine, *848 and carbohydrate tolerance, *766-767

and chorionic "growth hormone-pro-lactin," *846 and corticotropin, *70 and diabetes, *366 and corticotropin, "70 and diabetes, "366 and diet, "368 and glucagon, "434, "535 and glucose and insulin, "528 and growth hormone, 30-42, 749-757 and hypokalemia, "842 and hypophysectomy, "610 and insulin, 346-349, "544, "609, 633-634 and insulin, antagonism, 380-386 and insulin antagonism, 380-386 and ketone bodies, *136 in lipoatrophic diabetes patient, 263,

266-267

FI

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 October, 709-774 February, 73-142 June, 373-442 March, 143-232 July, 443-554 November, 775-854 December, 855-920 April, 233-302 August, 555-622

and lipoprotein lipase study, 567-568 metabolism, *137, *292 and nicotinic acid, *914 and nicotinic acid, *914
peripheral metabolism in glucose
tolerance tests, *124-135
and prediabetes, *519, 881, 884
and protein ingestion, 304
and protein synthesis, *516-517
and synalbumin antagonism, 390, 393-394 and glucagon and epinephrine, *529 and hyperketonemia, 723-724 of human milk, *228 incorporation into esters and hormones, metabolism and growth hormone and dexameth-asone, *135-136 mobilization and starvation, *526-527 nonesterified and carbohydrate tolerance, *766-767 and glucagon, 746 and insulin deficiency, 452 anl liver uptake, *767 and smoking, *849 and starvation, 804 synthesis, 632 and insulin, *291, 443-449 and liver, 637 and nerve metabolism, 698 and tricarboxylic acid cycle metabo-lism, *844 of alloxan-diabetic mice, 196-203

itus.

ome.

94

etes.

thy,

and

251.

535,

nide

etes,

73

04

766-

-pro-

-757

609,

263,

6

growth hormone transfer to, *435 guinea pig and insulin antibodies study, *768 insulin-I-131 turnover and antibodies to insulin, °768 insulin-I-131 incorporation, °438-439 insulin production and maternal hyperglycemia, 466 liver galactokinase, 662 loss

and growth hormone, *295

and blood group of diabetic mothers, *436 and diabetic pregnancy, 83 and potential diabetes, *918 and maternal diabetes, *370 and serum growth hormone determina-tions, *292

FLUORESCEIN ISOTHIOCYANATE, *523

P-FLUOROPHENYLALANINE and glucokinase, *545

FOOD intake, and ruminants, 326, 335

P-FRUCTOKINASE and insulin deficiency study, 454 FRUCTOSE absorption and phlorizin, *226 and carbohydrate incorporation, *227 and diabetic kidney, *517 in cerebrospinal fluid, *918 and glucagon study, 190-191 gluconeogenesis, 638 and hypoglucosemia, *917 and plasma fatty acids, sugar and in-sulin, *439 uptake and alcohol, 570, 578

FRUSEMIDE and carbohydrate metabolism, blood pressure, *847

G

GALACTOSE in basement membrane, *512 and glucagon study, 190-191 and insulin secretion, 571 and leucine incorporation into insulin, *918 utilization, 662, 667

GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE, *844

GALACTOSEMIA screening test, *844

GAMMA GLOBULIN and antibody response study, *514 and detection of anti-insulin antibod-ies, *67 insulin-like activity, *228

GANGRENE of feet, *66 and lipoatrophic diabetic, 351 and pedal angiography, *525

GASTROINTESTINAL TRACT and blood insulin, *532-533 and expired air study, 777, 789 hormones normones and plasma insulin, °701 and insulin release, °522-523, °531 and microangiopathy, °913 mucosa, and insulin release, 627 and tolbutamide and chlorpropamide, 272-273, 274

and diabetes, 17 and high-amylose corn starches digestibility study, 679, 690

GLOMERULI of diabetic Chinese hamsters, *547 of juvenile diabetics, 62 mesangial thickening and hemochromatosis, *513

GLOMERULONEPHRITIS and prolonged hypoglycemia, 363

GLOMERULOSCLEROSIS

and alloxan diabetes, 258-261, *437 and basement membrane, 61-63 and blood vessels of skin changes, 247 and diabetic hamsters, 331-334 and diabetics and nondiabetics, *434 etiology, *292-293 and hemochromatosis with hyperglycemia, *513 and lipoatrophic diabetes, 352, 353 and pancreatitis, *703 and panhypopituitary and diabetic pa-tient, 421-422

GLUCAGON and 3',5'-AMP, 633 and blood insulin, 558 and diabetic pregnancy, 833 and diazoxide, 320 and fat mobilization, 917 and fatty acid release, 347 -free insulin, 124 and gluconeogenesis, 188-192, °439 and glucoregulatory hormones, 500-505 and glucose metabolism, 183-187, *434 and glucose output, *530 and glycogen storage disease, *529 and hepatic lipase, *517 and hyperglycemia, 319

and insulin action, 643 and insulin and glucose, 855-865 and insulin secretion, °69, °370, °521, °521-522, °522-523, °532-*521-522, *522-523, *532-533, *545-546, 571-577, 625, 627, *918 -like activity

and pancreatic A-cell tumors, 709-712 and lipids, °535, 740-746 and lipolysis inhibition, °765 and pituitary growth hormone, *436 and serum insulin and insulin secretion, °515 plasma glucose and free fatty acids, °434 and starvation, *527 tolerance

and hyperadrenocorticism, 25-27 GLUCOCORTICOIDS and glucose tolerance tests, 880

GLUCOGENOLYSIS and liver glucose, 186

GLUCOKINASE assay, 475-478 and insulin, *545 and phosphorylation, 636-637

GLUCONEOGENESIS and alcohol, *526 and 2-deoxyglucose study, *434, *701 in diabetic and normal rat liver, 19-22 and diet and hormones, *226 and glucagon, 188-192, *439, *517

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 December, 855-920 April, 233-302 August, 555-622

and glucagon and insulin, 183-187 and hormones, 500-505 GLUCOSE

and alcohol, 570, 578 assays

semi-micro, *536 and blood insulin, °532-533 and blood pyruvate, *366-367 and cholesterol crystallization, *140 in diabetic kidney, *517

disposal and intestinal mucosa, 555-558

fatty-acid cycle and free fatty acids, °516-517 in vivo study, °515-516 and fatty acids, °292, °916 and free fatty acids and insulin, °528 in glomerular basement membrane,

m glomerular basement membrane **512 and glucagon, *69, *434 and insulin release, *370, 855-865 and glycogen formation, 492-495

and glycogenolysis in spayed rat uteri, *438

and growth hormone, *436, 749-757. °844

hepatic balance and insulin, *138 homeostasis, *69-70 and hypoglycemia, 362-364

infusion and diabetes, 630 and islet-cell response in diabetics and nondiabetics, °515

and obesity, °529-530 ingestion

and growth hormone, 907 and insulin

effect on potassium flux, *769 and glucagon and adenosine triphosphate induction, °917 release, °521-522, 625, 626 response, 304, °704, 867-873 secretion, °531, °545-546, °767

kinetics, and phenethylbiguanide, 173-177 and leucine incorporation into insulin, *918

and lipids, *535

-loading in amino acid metabolism study, 5-7 and hypoglycemia, 1-4 and insulin release, *536

and plasma free fatty acids, *366 metabolism

metabolism and obese rats, *611 and starvation, *844 and myocardial infarction, *138 and obese patients, *433 and octanoate infusion, *369-370 and pancreas islets' oxygen consumption, *366 and plasma fatty acids, sugar and insulin, *439 production

production

and glucose loading in normals and diabetics, 778-788

and glycogen storage disease, *519-520

and protein, 918 and hormone release,

pyruvate-3-C-14 and L-alanine-C-14 in-corporation, *226 renal reabsorption and tolbutamide, 90-

response and epinephrine, *434

and phenethylbiguanide, and phenformin, *544-545 and secretin, *701

synthesis in diabetic and normal rat liver, 19-

and glucagon, 188-192

tolerance

and age, °539, °845 and birth weight, °702-703 and Cherokee Indians, °439 and chlorpropamide, °228-229 and chromium, °539-540, °846

and chromium, °539-540, °846 and Delalutin, °914 and diet, 105-113 and estrogen, °914 and growth hormone secretion, °551

guanethedine in thyrotoxicosis,

and heart disease, *68 and hypertriglyceridemia, *843 in kwashiorkor, *225-226 and myocardial infarction, *294

and myocardial infarction, \$294 and obesity, \$438 and starvation, 800-801 and pancreatic A-cell tumor, 709 and pregnancy, \$532 and protein-calorie deficiency, 78-88 and tolbutamide, \$65, \$542 tolerance tests, \$438

and acetone poisoning case, 810 and amino acid levels, °544 blood sampling technic, °611 and children of diabetic parents,

881-886 and Chinese hamsters, *534 in diabetes survey, 13, 164-170 and diazoxide therapy, *841

and Dupuytren's contracture, °547 and family history, °541 in growth hormone-induced diabetes study, 31 and high-fat diet, *766-767

and hyperadrenocorticism, 24-25, 27-

insulin-induced hypoglycemia study, 308 for "K" value determination, *66 and magnesium deficiency, 734-738 and mental patients, 97-103

and necrobiosis lipoidica, *368 new carbohydrate solution for, 762 after pancreatectomy, 179-181

and peripheral glucose metabolism, •134-135, •135 and plasma and whole blood meth-ods, 775-777

and prediabetes, *518-519 and pregnancy, *433, *525 and chronic hypoxia, 130-132 and reactive hypoglycemia, 1-4 reproducibility, 901-904

and serum immunoreactive insulin, °518 and siblings of diabetic children, 401-402

in skin capillary study, 253 and spontaneous remissions, and survey in Michigan, *535

and tolbutamide tolerance test compared, 212-218
and triamcinolone glucose tolerance tests, 726-728

transfer and insulin and diabetes, *609 transport

in human pregnant uterus, *370 and insulin, 377 and tumors, *701

turnover and L-leucine, *703 untake

and albumin, 389, *540-541, *542-543, *609, 835-837 of brain and spinal cord, *844

and "bound" insulin, 889 and burns, *227 and diazoxide and chlorothiazide,

and growth hormone, *439 and insulin, *65, *540 and insulin antagonism, 153-156,

380-386 and lipoatrophic diabetes, 354 and nicotinic acid, °64 and placenta, °534 and rat adipose tissue, 430-431

of rat epididymal fat pad and hemi-diaphragm, 360-361 urine tests, 127-129

utilization and "bound" and crystalline insulin, °610

and obesity, *915-916

GLUCOSE-C-14 conversion to C-14-O2, *67 and glucose loading study, 778-788 and hypoglycemia, 768 incorporation into glycogen and synalbumin, 660 incorporation into muscle and bound insulin, *843-844 metabolism

and islets of Langerhans, *137 and lipoma tissues, 808-809

GLUCOSE-1-C-14 incorporation, 894 and insulin-like activity assay, *438

GLUCOSE OXIDASE METHOD, 1, 160-163, 184, 555-558

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72

February, 73-142 March, 143-232 April, 233-302

May, 303-372 June, 373-442

July, 443-554 August, 555-622 September, 623-708

October, 709-774 November, 775-854 December, 855-920

GLUCOSE-6-PHOSPHATASE and glycogen storage disease, 406 in protein-calorie deficiency study, 81, 83

GLUCOSE-6-PHOSPHATE, 267 and glycogen synthesis, 492 and insulin, °764

GLUCOSE-U-C-14 incorporation into muscle and bound insulin, °433 metabolism, °295

ulin.

dren,

66

com-

ance

0

542-

zide.

-156,

emi-

ulin,

88

38

160-

GLUCOSTEROIDS and insulin response, 627, 630 and lipolysis, 642

GLUTATHIONE-INSULIN TRANSHY-DROGENASE, 645

GLYCEMIA and family history study, *535 and nialamide study, 687

GLYCERIDES and diet, *227, *368

GLYCEROL and insulin, 314 release and beta-hydroxybutyric acid, °433 and nicotinic acid, °64

GLYCINE incorporation into protein, 376 and insulin release, 44-50, 630 and protein synthesis, 121

GLYCINE-1-C-14 incorporation into protein, 119-120

GLYCINE-2-C-14 incorporation into protein, 377

GLYCODIAZINE, *140 and adult-onset diabetes, *530-531

of anterior pituitary
and insulin, 118-119, 121
assays
and obesity, °530
in beta cells
and insulin antibody study, 207-208
and diazoxide, 321, 322
formation
and age and obesity, °610
and insulin and glucose, 492-495
and histamine, °369
and hypokalemia, °842
and insulin, °138
and lactate metabolism study, 424
-laden hepatomegaly, °293
metabolism, °532
in muscle and adipose tissue
and bound insulin, °433
nephrosis
in diet-induced diabetes, 108, 110

and phenethylbiguanide, 173
and protein-calorie deficiency, 80-81,
83
storage disease
and diazoxide, 406-410, *841
and endogenous glucose production,
*519-520
and glucagon and epinephrine, *529
synthesis, 492
and albumin, 389, *542-543, 835837
and 'bound' insulin, 889, 894
and 2-deoxyglucose, *434
and enzymes, 636, 637
and estradiol, *769
and rat hemidiaphragm, 274, 376
and synalbumin antagonist, 648
and trypsin, 342

GLYCOGENESIS and age and stress, *703 and pituitary and insulin, 115-121

GLYCOGENOLYSIS and allexan-diabetic spayed rat uteri, *437-438 and diazoxide, 321 and epinephrine, 27, *434 and glucagon, 746 and hyperglycemia, 188 and liver, 636-640

GLYCOLYSIS and citrate, 394 and phenethylbiguanide, *520 and pyruvate, 19

GONADS and diabetes, *537

GOUT and diabetes, *918 and glycodiazine study, *140 and hyperuricemia and diabetes, *487

GROWTH HORMONE and acromegaly, *367

assays, *540 in lipoatrophic diabetes, 265 and diabetes, 373, *609 and diazoxide, 320 and fatty acid release, 347 and glucoregulatory hormones, 500-505 and glucosteroids, 642 human and bovine and immunologic cross reaction, *846 and hyperostosis, *916 and hypoglycemia, 5, 307 -induced diabetes and serum insulin levels, 30-42 and insulin, *439, 905-909 in acromegaly, *365 in acromegaly, *365 immunoassay, °514 release, °516 response, 627 secretion, 749-757 sensitivity, °438 insulin-like effect, °766-767 and ketosis, °526 and lipolysis 633 °764 and lipolysis, 633, *764 and glucose metabolism, °701 and metabolism, °135-136 in mother and fetus, °292, °295, °435 and panhypopituitarism with diabetes, and pregnancy, *610 radioimmunoassay, *702 and kidney disease, *546 response to amino acid and sex, *917 and retinopathy, 77, *543-544 secretion and glucose, *844 and glucose tolerance, *551 and sex and estrogen, *291-292 and starvation, *527 and urea production, and lipid and glucose metabolism, *517 and urine hydroxyproline, 134

GUANETHEDIONE and glucose tolerance in thyrotoxicosis, *769

H

HEART cholesterol and serum cholesterol, 829 of diabetic with Sheehan's syndrome, 75 in lipoatrophic diabetes case study, 262 in long-standing diabetes, 278

HEART DISEASE and alcohol and liver disease, 570, 578 coronary and carbohydrates, *64 and growth, 470, 496 and insulin release and glucose tolerance, *68

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

HEMOCHROMATOSIS and pancreas alterations, *513

HEMORRHAGE and photocoagulation, *611 subarachnoid in panhypopituitary and diabetic patient, 420

HEPARIN and carbohydrate tolerance, *766-767 and diabetic osteopathy, *535

HEPATOMEGALY glycogen-laden, *293 olycogen storage disease, 406,

HEPATOSPENOMEGALY and lipoatrophic diabetes, 262, 351

and beta-lipoprotein deficiency, 268 and chromosome study of diabetics, *765 and diabetes, *70, 419, *916 and juvenile diabetics, 400-404 and sucrose intolerance, *368-369

HEXOKINASE, *518 assay, 475-479

HEXOSAMINE in basement membrane study, *512

and insulin secretion, 571-577 monophosphate pathway, °765 phosphotransferase in rat liver, °917

HEXOSE-6-PHOSPHATES and glucose metabolism, *517-518

HISTAMINE and glycogen, *369

and growth hormone, °67 and insulin, 7, 44-50, 627

HORMONES and adipose tissue metabolism, *139 adrenal cortex and gluconeogenesis, 19-22 diabetogenic, *609 and fatty acids, 347, *916 and gluconeogenesis, 183-187, °226 glucoregulatory, 500-505 and impotency, °537 and insulin secretion, 571-578, 627, 629-630 intestinal

and plasma insulin, *701 and lipid response, *765 and lipolysis, 633, *764 and glucose metabolism, *701 lipolytic

and lipolysis, *294

peptide and muscle permeability to sugar, *516

of pituitary gland, *913 and diabetes in rats, *609 release and glucose, and protein, *918

and growth hormone levels, *540 and starvation, *527

HYDROCHLOROTHIAZIDE and blood glucose, *546 and blood sugar, *140

HYDROCORTISONE
-induced diabetes, *436

HYDROXYBUTYRATE and hypoglycemia, 811 and ketosis, 357

17-HYDROXYCORTICOIDS in insulin-induced hypoglycemia, 308

17-HYDROXYCORTICOSTEROID, 24 and diazoxide-induced diabetes, 319

HYDROXYPROLINE, *134

HYPERADRENOCORTICISM and carbohydrate metabolism, 24-29 and insulin response, 867 and pancreas beta cells, 491

HYPERCHOLESTEROLEMIA and diabetes, 604-608

HYPERGLYCEMIA and acetone, 810-811 alimentary and insulin-induced hypoglycemia, 307-313 and alloxanized pregnant mice, 195 and amino acid metabolism study, 7 and arterial disease, *137 and ascorbic acid, *228 and burns, *227 and 2-deoxyglucose, *434 and Dextrostix test, *225 and diabetic retinopathy, °437 and diazoxide, 143-148, °295, 406, °841 and diet, 631 and diet-induced diabetes, 109 and diphenylhydantoin intoxication, *916 and epinephrine and glucagon, 319 and epinephrine hyperkalemia, *226 in forearm skin capillary study, 251 and glomerulosclerosis and hemochro-matosis, *513 glucagon-induced, *69 and glucagon, 188-192, *522-523, 627,

860 and glucose and glucagon study, *434 and glucose tolerance tests, 762

in growth hormone-induced diabetes, 34, 41

and hyperadrenocorticism, 25 and insulin and insulin antibody study, 205 deficiency study, 454 release, and age, *539 response, *519, 573, 867 and islet cell adenoma, *847 and ketosis, 760-761 and lipoatrophic diabetes, 351, 353 maternal and fetal insulin production, 466 and morphine, *68 and nervous system, *522 and nonthiazide diuretics, *550 and obesity and "bound" and crystalline insulin, *610 and pancreatectomy study, 180-182 portal and blood insulin, *532-533 in rabbits immunized with insulin, 582-584 in severe diabetes, 219 and sulfonylureas, *64 and tongue surface test, 58-60

H

H

Н

H

H

H

HYPERGLYCERIDEMIA and glycogen storage disease, *519-520 and insulin resistance, *226

HYPERINSULINEMIA and age, *539 and glucagon, 855-865 and glucose regulation, 504 and growth hormone-induced diabetes, 40 and hyposomatrotropinemia, 505 and obesity, 303 and tolbutamide, *545

HYPERKALEMIA, 695-696

HYPERKETONEMIA and insulin release, *438 and renal and parotid urate excretion, *539 triglyceride-induced, 723-724

HYPERLIPEMIA, *524 carbohydrate-induced and insulin response, 867 and starch and sucrose, *433-434 and diabetes, 675-678 and family history, *917 in glycogen storage disease, 407-408, in lipoatrophic diabetes, 262, 351, 354 and lipoprotein lipase, 565-569

HYPERMETABOLISM and undernutrition in children, 470, 496

HYPEROSTOSIS, *916

HYPERPHAGIA and diet-induced diabetes, 112 in goats, 326

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142 March, 143-232

April, 233-302

May, 303-372 June, 373-442 July, 443-554 August, 555-622

September, 623-708 October, 709-774 November, 775-854 December, 855-920

HYPERPLASIA adrenal, 24 islet cell and neoplasms, *136

HYPERSOMATOTROPISM and insulin response, 867

HYPERTENSION and blood vessel changes, 247 and carbohydrate tolerance, *226 and diabetes and Achard-Thiers syndrome, *436 and frusemide, *847 and hyperlipemia, *433 and myocardial infarction, *293 and retinopathy, *548 and serum insulin, *704 and sex, 507-510

HYPERTHYROIDISM and diabetes, *68-69, 278, *548 and guanethedine, *769 in skin capillary study, 253 and tolbutamide and glucose tolerance tests, 215, 218

HYPERTRIGLYCERIDEMIA, 631 and glucose tolerance, *843

HYPERURICEMIA and glycogen storage disease, *519-520 and gout and diabetes in Polynesians, *437 and ketoacidosis, 357-358

HYPOGLUCOSEMIA prevention of, *917

0

HYPOGLYCEMIA and acetoacetate, 811 and acetohexamide, 362-364 and butazolidine, °520-521 and Actrapid and Crystal II insulin, °64-65 and adrenal carcinoma, *769 and alcohol, *526 and alloxanized pregnant mice, 196 and ascorbic acid, *228 and blood glucose tests, 212 and children of diabetic parents, 882 and children of ulabelia and chymotrypsin, 626 and coma and mannitol therapy, *435 and coma and mannitol therapy, *70 and corticotrophin deficiency, and Dextrostix test, *225 onset, 880 and diabetes

and infants

and diarrhea, *846-847

and insulin assay, *294-295 insulin-induced and alimentary hyperglycemia, 307-313

and glucose-carbon atoms in mouse, •768 and growth hormone, epinephrine

and cortisol, 5 and pituitary-adrenal function test, •916

and ketoacidosis, 504 and leucine, 560-564 leucine

induced, *136 -sensitive, and diazoxide, 319 and L-leucine, 223 in long-standing diabetes, 278

monoamine-oxidase inhibitors,

and myocardial infarction, *138 and nervous system, *843 and new blood-sampling technic, 75 and oral insulin administration, *551 and pancreatic excretory obstruction, °436

and pancreatic resection, *138 and parotid gland enlargement, *769 and phenethylbiguanide, 173-177 and phenformin, *1 and phloridzin, 502 •136 reactive

and plasma insulin levels, 1-4 and retroperitoneal mesothelioma, *135 and serum insulin studies, *703 spontaneous and tolbutamide and glucose toler-

ance tests, 215 and sulfated insulin, 458 and sulfonylureas, 273 and tolbutamide therapy, 279, *845 and tumor, *70 and uremia, *520

HYPOGONADISM and family history, *917

HYPOKALEMIA and acidosis, *843 and carbohydrate metabolism, free fatty acids, potassium and glycogen, *842 and islet cell adenoma, *847

HYPONATREMIA and diazoxide, 320

HYPOPHYSECTOMY and "bound" insulin study, *843-844 cryogenic, *0702 and diabetes, 373 and diabetic blindness, *437 and diazoxide hyperglycemia, 320 and fatty acid incorporation, *916 and free fatty acids, 349 and growth hormone, *436 and insulin, *769 biosynthesis, *549-550

and lipid metabolism, *609-610 and nonsuppressible insulin-like activity, 647 and pregnancy, *542 and retainpathy, 77 trans-sphenoidal, *66 and urinary hydroxyproline, *134

HYPOPHYSIS tumors and growth hormone secretion, 504

HYPOPITUITARISM and diabetic pregnancy, °542 and diabetic retinopathy, 133 and diazoxide-induced diabetes, 319and growth hormone and insulin study, *365 and hypophysectomy and growth hor-mone, *134 mone, *134 induced, in diabetic retinopathy, *66-67

HYPOSOMATOTROPINEMIA, 505

HYPOTENSION and diabetes with pituitary insufficiency, 73 and sex, 507-510

HYPOTHALAMUS and gluconeogenesis, *434 and insulin release, *536 and lesions, 465, 491 and metabolism, 326, 335

HYPOTHERMIA and epinephrine, *434 and liver electrolyte and glucose, *226

HYPOTHYROIDISM and Achilles reflex, *436 and diabetes, *68-69 and sulfonylurea-treated diabetics, *67

HYPOXIA and congenital malformations, 199-202 and glucose tolerance, 130-132

I

IMMUNIZATION against insulin and placenta transfer of insulin-I-131, *768 and pregnant guinea pigs, *768

IMMUNOELECTROPHORESIS and serum proteins, 150

IMPOTENCE and diabetes, *291 and autonomic nervous system, *537-538 and gonadal function, *537 and diabetic neuropathy, 93

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 June, 373-442 October, 709-774 March, 143-232 November, 775-854 July, 443-554 April, 233-302 December, 855-920 August, 555-622

INFANTS of alloxanized mice congenital malformations, 194-203 and atherosclerotic lesions, 8 and diabetes onset, 880 and diabetes survey, 14-15, 17 and glucose tolerance study, °702-703 and maternal diabetes, *366 birth weight and blood glucose level of mothers, 466 and congenital heart disease, 470, 496 of diabetic mothers, 728, 833-834 and hypoglucosemia, *917 and hypoglucosemia, 911 and islets of Langerhans, 812 and plasma insulin, insulin antibody, and glucose study, *847 and hypoglycemia, *546-547, *703 and diarrhea, *846-847 and nervous systems, *843 and islet-cell hyperplasia, *138 newborn serum magnesium levels, 739, 748

INSULIN activity, *915 and "bound" insulin, *433 and starvation, *69-70 Actrapid and Crystal II study, *64-65 and adipose tissue electrical potential, *291 metabolism, *139 administration and immunological response in cattle, *766 oral, *551 adsorption, *439 and albumin and glucose uptake, *540-541 and alloxanized pregnant mice, 194-203
and amino acids, 5-7, *139, *544
antagonism, 149-158, 287-288
and albumin, 373-378, 835-837
assays, 380-386, *514
and diabetes, *292-293
and insulin uptake, *540
and myocardial infarctions, *68
and pancreatic diabetes, *227
and synalbumin, 388-398, 400-404,
*535-536, *546-547
antibodies, 668-674, *763
and pancreas studies, 205-211 203 and pancreas studies, 205-211 in pregnant guinea pigs, *768 and diurnal pattern, *765 and hypoglycemia, *294-295 and pancreatic homografts, *702 and pancreatic proteins, 342-345 augmentation study, *228

-binding index in juvenile diabetes, 276-277 biosynthesis study, *549-550 and blood glucose, 123-125 and blood pyruvate, *366-367 bound' assay, 894-899 and crystalline, and glucose utiliza-tion, *610 and hypophysectomized and adren-alectomized rats, *843-844 and insulin uptake, *513-514, 655-661 rat serum, 889-892 crystalline and "bound" insulin, 655-661 deficiency and fatty acid and protein synthesis, 443-449 and hepatic glycolytic and Krebscycle intermediates and puridine nucleotides, 451-455 degradation, *916-917 and diabetic acidosis, 695 and diabetic Chinese hamsters, *534 and diabetic coma, 714-720 and diabetic tree shrews, 330 disposal and kidney, 680-685 dosage and acidosis, *369 and diabetic pregnancy, *542 and errors, *525-526 in glomerulosclerosis study, 259-261 edema syndrome, *769 endogenous and cortisol effects, *533 and fatty acid incorporation, *916 and fatty acid synthesis, *291, 698 fluoresceinthiocarbamyl, *523 free and bound, 287 and free fatty acids and glucose, *528 metabolism, *292 release, 314 and glucagon and glucose, 855-866 and glucokinase, *545 and glucoregulatory hormones, 500-505 and glucose and amino acid metabolism, *294 and free fatty acids, *609

and free fatty acids, *609
and glucagon and adenosine triphosphate induction, *917
hepatic balance, *138
metabolism, 115-121, 183-187, *365
uptake, *65
and D-glucose 6-phosphate and D-lactic acid in rat tissues, *764
and glycogen formation, 492-495
and growth hornone, *67, *543-544, 905-909
and acromegaly, *365
immunoassay, *514
and hepatomegaly, *293
and hexokinase, *518

immunoreactive and age, *845 and exercise, 838-840 and glucose infusion study, *515 and hypoglycemia study, *703 and infant hypoglycemia, *846 and prediabetes, 880 release, *918
-induced hypoglycemia, *70 and alimentary hyperglycemia, 307-313 and glucose-carbon atoms in mouse, *768

as pituitary-adrenal function test, °916
inhibition
and albumin, °609
inhibitors, °532
injections
and pancreas islets, 823-828
methods, °611
insufficiency
and phosphoenolpyruvate carboxykinase, 19-22
and juvenile diabetics, 411
and islets of Langerhans, 586-594
and kidney disease, °546
and kidney disease, °546
and kidney lesions in alloxan-diabetic
rats, °437

R

re

in

a

rese

Lente and diabetic pregnancy, 831-832 leucine incorporation into and sugar, *918 -like activity and adrenalin. *138 and anti-insulin antibodies, *139-140 assay, *438 assay, 439 bioassays, 439 and "bound" insulin, 894-899 and diazoxide, 147 of enzymes, 342-345 and immunoreactive insulin, *294 of pancreatic homografts in hamsters, 51-57 and plasma, *542-543 in serum proteins, *69 in tumor tissue, *70 and tumors, *294 and urine protein, *524 and lipemia, *524 in lipoatrophic diabetes, 263, 264

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

beta chain

beef and pork

and glucose uptake, *540

and synalbumin antagonist, 397-398

and dermal reactions, 790-796

and lipogenesis, 346-349, *533-534 and lipolysis, *294, *433 and lipomas, 807-809 and liver fatty acid synthesis, *610 and liver metabolism in normal and diabetic rats, *767 metabolism and uremia, *138 monkey, *769 and muscle permeability to 3-methyl-glucose, *292 and myocardial infarction, *138 and neuropathy, 473 NPH and lipoatrophic diabetes, 351 and pancreas homograft study in hamsters, 51-57 and peridontal disease in Chinese hamsters, **531 and serum lipids, **536-537 and parotid gland enlargement, *849 overdose and coma, *435 and pancreatectomy study, 180-181 and permeability of muscle to sugar, °516 phenethylbiguanide study, 173, 175-176 and phenformin, *136 and potassium exchange in muscle, and potassium flux and muscle water and electrolyte, *769 Protamine Zinc and alloxan-diabetic acidosis, 423 and protein synthesis, *701 radioimmunoassay coated charcoal, *227 Regular and crystalline protamine, 219-221 and juvenile diabetes, *550-551 release and benzothiadiazine, *765 and beta-adrenergic receptor, *543 and chelating agents, 44-50 and diazoxide hyperglycemia, 321 and gastrointestinal tract, *522-523 and glucagon, *370, *918 and glucagon, 570, 518 and glucose, glucagon and potas-sium, *521-522 and growth hormone, *516 and heart disease, *68 and hyperketonemia, *438 and intestinal mucosa, 555-558 and leucine, *136, 560-564 and L-leucine, *703 in pregnancy, *140 and thyrotoxicosis, *769 requirements in diabetes with Sheehan's syn-drome, 73 in long-standing diabetes, 277-278 and phenformin, *611 and thyroid disorders, *68-69 and cbesity, *529-530

resistance and "bound" insulin, °64 and coma, °548 in hyperglyceridemia, °226 and insulin antibodies, *764 and lipoatrophic diabetes, 351 and obesity, *915 treatment for, *140 and albumin, 388-398 and children of diabetic parents, 885 and diazoxide and chlorothiazide, °365 and free fatty acids, *766-767 to glucose, *704 to glucose and tolbutamide, 867-873 to hyperglycemia, °519 to ingested protein, 303-306 and muscle, °702 and phenethylbiguanide, °764 in rat adipose tissue, 430-431 and renal insufficiency, *229 and ribonucleic acid and protein syn-thesis, *848 and secretin, *845-846 secretion and cations, 910-912 cingulate gyrus stimulation, and diazoxide, *435 and tolbutamide, *523 endogenous, *521 and glucagon, *69 and epinephrine, *515 and glucose, *531 and growth hormone, 30-42, 749-757 and hexoses, epinephrine and glucagon, 571-577 in hypoglycemia, 1-4 and insulin infusion of pancreas, 123-125 and intestinal hormones, *701 and intestines, *293 and obesity, *433 in rabbits, *536 in rat pancreas, *521, *767 and secretin, *768 and starvation, *527, 798-809 stimulation of, *545-546 and sulfonylureas, 362 and vagus nerve stimulation, *522 sensitivity
and brain, *844
and peripheral glucose metabolism,
*135
**ains. 331-334
in tree and serum proteins, 331-334 and spontaneous diabetes in tree shrews, 328-329

and hexose monophosphate pathway, °765
and secretion, 623-649
storage, release, transport and antagonism, 281-289
syringes, incorrectly marked, 193
and tolbutamide, 90, 663-666
tolerance
and hyperadrenocorticism, 25
tests, °537-538
and protein-calorie deficiency, 79-80
and thyrotoxicosis, °916
transfer
and placenta, °534
and triglycerides, °437
and free fatty acid metabolism, °137
uptake
and "bound" insulin, °513-514
INSULIN-I-125

INSULIN-I-131
degradation
in lipoatrophic diabetes, 265-266
incorporation
and 1-methyl-2-mercaptoimidazole
and perchlorate, *438-439
and insulin disposal study, 680
metabolism, 336-341
placental transfer
and antibodies to insulin, *768

and insulin disposal study, 680-685

and mouse tissue assay, *533

and insulin immunity study, 813-815

INSULINOMA and diazoxide, 406 and hypoglycemia, 364 and leucine, *136

INTESTINES
and diabetic neuropathy, 93-96
fat absorption and protein synthesis,
268
and insulin secretion, *293
mucosa
and insulin release, 555-558
sucrose deficiency, *368-369
sugar transfer
and phlorizin, *365

ISLETS OF LANGERHANS
of diabetic tree shrews, 328-329
and diet-induced diabetes, 109
fibrosis
and insulin immunization, *768
and glucose metabolism, *765
and hyperglycemic nonketotic coma,
*65
hyperplasia
congenital, *435
hypoplasia
in panhypopituitarism with diabetes,
421

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

and deamidation, 875-879

465 and surgery for diabetics, *66 synthesis, *367

and beta cells, 281

and insulin-resistant diabetes, 457-

sulfated

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

and infants of diabetic mothers, 812 and insulin injections, 586-594 metabolism, *9137 in pancreas homografts in hamsters, 52-57

postnatal neogenesis, 480-490 and protein-calorie deficiency, 86 and tolbutamide and postnatal neogenesis, 597-602

ISOLEUCINE and growth hormone, *67

ISOPROPYLNOREPINEPHRINE and insulin release, 629

JAPAN rice-meal test and glucose tolerance test study in, 901-904

K

KETOACIDOSIS and burns, *227 and diazoxide, 320
-induced diabetes, 319-322
and growth hormone, exercise, starvation and hypoglycemia, 504 and insulin resistance, *140, *548 secretion, 504 and juvenile diabetes, *847 and lipoatrophic diabetes, 351 and lipoprotein lipase study, 565-568 and mortality, *365-366 and uric acid excretion, 357-358

KETOGENESIS and calorie deficiency, *66 and glucagon, °517

α-KETOGLUTARATE and glucose formation, 19

KETONEMIA and uric acid, 357-358

KETONES Acetest, 106 and diabetic Chinese hamsters, *534 and diet, 335 and diet, 335
and free fatty acid, *136
and glucagon, 746
and growth hormone, *517
and hyperglycemia, 811
and juvenile diabetes, *703-704
in ketoacidosis study, 357-358
and lipoatrophic diabetes, 354
and nonesterified fatty acids in diabetic and normal rat liver,
*767
and staystion, *533 and starvation, *533 and tricarboxylic acid cycle metabo-lism, *844

KETONURIA in alloxan-diabetic monkeys, 261 and diabetic pregnancy, 830 and diazoxide-induced diabetes mellitus, 319 tus, 319 in diet-induced diabetes, 106 and fasting, °438 in insulin antibody study, 207 and lipoatrophic diabetes, 351 and retinopathy, °548 and serum uric acid, 357-358 in sulfonylurea study, 270-272

and alloxan-diabetic acidosis, 423-424 and diabetes, 373, *917 and diabetes, 373, *917 and diabetic pregnancy, 833 diagnosis, *538 and diazoxide, 322 and hyperglycemia, 760-761 and hypophysectomy, *610 and lipoatrophic diabetes, 262, 354 in severe diabetes, 219 and starvation, *526-527 and sulfated insulin, 459 and sulfonylureas, 269 and urate excretion. *539 and urate excretion, *539 and xylitol, *140

17-KETOSTEROIDS, 24

KETOSTIX, 424

KIDNEY and alloxan-diabetic rats, *437 and amino acids, 7 and carbohydrate metabolism, *138 and diabetes, *517 and diabetic neuropathy, 95 disease and diabetic mortality, °228 and diabetes with Sheehan's syn-drome, 73, 74 and diabetes survey, °227 and growth hormone and insulin, *546 and insulin requirement, 341 in panhypopituitarism and aiabetic patient, 420 and retinopathy, *548 and sulfonylureas, 362-364 function and lipoatrophic diabetes, 354 glomerular intercapillary spaces, 251 glucose reabsorption and tolbutamide, 90-92 and hemochromatosis, *513 insufficiency and glycoregulation, *229 and hypopituitarism, 133 and insulin and insulin
disposal in dogs, 680-685
-injected cows, 593
metabolism, 336-341
lesions, *913
and basement membrane study, *512
in lipoatrophic diabetes, 263
and proteinuria, *435
urate in hyperketonemia, *539 KIMMELSTIEL-WILSON'S DISEASE, 262-267 in diabetics and nondiabetics, *434 in diabetic Chinese hamsters, *547

LEU

LEU

LEU

LIPI

pi

ar

an

ca

an

in

LIPI

an

an

of

me

mo

red

and

tra

LIPO

LIPO

and

and

and

and

and

cort elec

and and

and inhi

and and

LIPO and

and

KREBS-CYCLE INTERMEDIATES and insulin deficiency, 451-455

KWASHIORKOR

and carbohydrate metabolism, *225-226 and protein-calorie deficiency, 78-88

L

LACTATE and lipase, 633 metabolism, and alloxan-diabetic acidosis, 423-429 -pyruvate ratio, and alcohol, 578 uptake by liver, and insulin, *767

LACTATE-1-C-14 and glucagon study, 190

LESIONS

LACTOGEN placental, and growth hormone, *610

LACTOSE and carbohydrate intolerance, *609

atherosclerotic and cholesterol, *140 and diabetic, 114, 126 fine structure, 8 cardiovascular, and diabetes and ser-um cholesterol, *512-513 and diabetic osteopathy, *534-535 foot. *543 gastrointestinal tract, *923 glomerular, 257, *512 in alloxan-diabetic monkey, 258-261 in Chinese hamster, *547 hepatic, and sulfonylurea therapy, 273hypothalamic ventromedial, and obesity, 465, 491 periodontal, and diabetic Chinese hamsters, *531 vascular

LEUCINE and glucose turnover, *703 and growth hormone, *67 and hypoglycemia, *136, 560-564 incorporation into insulin, *918 into protein, *848 and insulin

and diabetes, *65-66, *68, *136

and insulin
degradation, *916
-like activity, *294
release, 44-50
sensitivity, and hypoglycemia, 319, 406
and sulfonylurea failures, 222-223 tests, *229

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 June, 373-442 October, 709-774 March, 143-232 July, 443-554 November, 775-854 April, 233-302 August, 555-622 December, 855-920

LEUCINE-C-14 protein incorporation, *701

LEUCOPENIA and sulfonylureas, 273, 274

LEUKEMIA and carbohydrate tolerance, 218

LIPEMIA, *524 carbohydrate-induced, and glucose tolerance, 631 and dietary carbohydrates, *64 in rabbits immunized with insulin, 582-583

0

LIPOATROPHIC DIABETES, 262-267 and insulin antagonism, *702 and retinopathy, nephropathy, and neuropathy, 351-355

and puromycin, 268

LIPOGENESIS and diabetic rabbit sciatic nerve, *533-534 and insulin, *291, 346-349 deficiency, 443-449 and lipoatrophic diabetes, 354 and pituitary and insulin, 115-121

LIPOLYSIS
and beta-hydroxybutyric acid, *433
and chorionic "growth hormone-prolactin," *846
corticotropin-induced, *841-842
electrolyte-activated
and calcium, *914
and glucagon and glucose, *535
and growth hormone and dexamethasone, *135-136
and hormones, *701
inhibition study, *765
and insulin, *433
and isopropylnorepinephrine, 629
and phospholipase-C and insulin, *294

regulation in adipose tissue, *764 and tolbutamide, 314

LIPOPROTEIN
of children of diabetic parents, 881
deficiency, 268
lipase
and diabetes and hyperlipemia, 565569
in lipoatrophic diabetic patient, 262

and acetic thiokinase, 697
cirrhosis
and hemochromatosis, *513
damage
and hypoglycemia, 363
in diet-induced diabetes, 109, 110
disease
and alcohol and heart disease, 570, 578
and fasting diet, 399
and hypoglycemia, 1, 2
and tolbutamide and glucose tolerance tests, 215, 218
electrolyte
and epinephrine, *434
fatty acid
and insulin deficiency, 443-449
and hypophysectomy, *610
free fatty acid uptake, and insulin, 317
function
and chlorpropamide therapy, *135
in diabetes survey, 99
and lipoatrophic diabetes, 354
and pancreatic carcinoma, *436
in sulfonylurea study, 273

glucokinase, °545 gluconeogenesis and alcohol, °526 glucose and 2-deoxyglucose study, °434 and electrolyte and epinephrine, °226 and glucagon stimulation, °530 and insulin, °138 metabolism, 183-187 output and free fatty acids, °515-516 and phenethylbiguanide, 173

and phonethylbiguanide, 173
phosphotransferases, 475-479
production, and hormones, 501
synthesis in diabetic and normal rats,
19-22
uptake, and diazoxide, *841
glycogen
and diabetic Chinese hamsters, *534
and diazoxide, 321
and ketones and starvation, *66
lipids and protein synthesis, 636-640

glycogen storage disease and diazoxide, 406-410 and endogenous glucose production, °519-520 and glucagon and epinephrine, °529 and glucagon and glucose infusion, °435

glycolytic and insulin deficiency, 451-455 hepatomegaly and ethyl chlorphenoxyisobutyrate, °64 and hypoglycemia and leucine, 563 and insulin degradation, 643 -like activity, *139-140 metabolism, 336-341 release, *293, *370 secretion, *531 lesions, *913 lipase and glucagon, *517 lipids and alloxan-diabetic acidosis study, 424, 427 and carbohydrate incorporatior, *227 in lipoatrophic diabetes, 262, 352, 353 metabolism and fat mobilization, 346-349 and growth hormone, *517 and insulin study, *767 perfused rat and growth hormone, *517 phosphorylase, *529 and protein-calorie deficiency, 81, 83-84 pyridine nucleotides and insulin deficiency, 451-455 and D-hexose phosphotransferase, and renal failure, *138 RNA, 639-640 and sulfonylurea therapy, 273-274, 275

glycogenesis and age, *703

and glucagon, 740-746

L-LYCINE-U-C-14
incorporation into protein, 446-448

in diabetes survey, 170-171

LYSINE and growth hormones, *67

tests

urea

LYSINE VASOPRESSIN and muscle permeability to sugar, *516

LYMPH and insulin activity, *369 insulin-like activity, *294

LYMPHOMAS and carbohydrate intolerance, 216, 218

M

MAGNESIUM deficiency and carbohydrate metabolism, 734-738 and insulin release, 626, 649, 911-912

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708
February, 73-142 June, 373-442 October, 709-774
March, 143-232 July, 443-554 November, 775-854
April, 233-302 August, 555-622 December, 855-920

MALATE and diabetes, *844 and insulin deficiency study, 452

glucose tolerance, nutrition, and dia-betes in, 9-17

MALNUTRITION and hypoglycemia, 363, *769, *843

MALONATE and glucose synthesis, 21

MALONYL SYNTHETASE and fatty acid synthesis, 448-449

MALTA diabetes survey in, *295

MANNITOL and coma, *435 penetration into squid axon, *67

MANNOHEPTULOSE and insulin release, 630

in basement membrane, *512 and glucose uptake, *65 and insulin secretion, 571 and leucine incorporation into insulin, *918

MANOAMINE-OXIDASE-INHIBITORS, *764

MARASMUS SYNDROME and protein-calorie deficiency, 78-88

MEBANAZINE and hypoglycemia, *764

MENSTRUATION and growth hormone levels, *540 and panhypopituitarism with diabetes,

MENTAL ILLNESS and diabetes, 164-172

MERCAPTOETHANOL and hexokinase, *518

MESOXALATE and insulin release, 44-50, 630

METABOLISM alcohol, 570, 578 amino acid amino acid
and insulin, 5-7
and 3'-5'-AMP, 641
and arginine, *848
and calorie intake study, 893, 900
carbohydrate, 874, 888
and ascorbic acid, *228
and burns, *227
and obles receiping, 103, 103 and chlorpromazine, 102-103 and corticotropin, *70

and diabetes, *918 and diabetic mothers and their infants, *917 and diazoxide, 321 and frusemide, °847 and hyperadrenocorticism, 24-29 and hypokalemia, °842 and insplin-induced hypoglycemia, in kwashiorkor, *225-226 and lipids and xylitol, *140 and magnesium deficiency, 734-738 and nagnesian dentency, 134-136 and nervous system, *522 and nialamide, 686 and phenothiazine therapy, 171-172 and prediabetes, 419 and pregnancy, *525 and progesterone, *913-914 and protein deficiency, 78-88 and renal failure, *138 and uremia, *320 catecholamine and diazoxide, 321 citrate and diabetes, *845

fat cells, *294 fatty acid and protein and insulin deficiency, 443-449 free fatty acid and catecholamines, glucose, and in-sulin, *292

glucose acetate

and obese rats, *611 and albumin, 388-398 of brain, *844 and caffeine, deoxyribose nucleic acid and insulin, *365

and chromium deficiency, *368 and 2-deoxyglucose, *434 and diabetic Chinese hamsters, *523-524

and glucagon and insulin, 183-187 and hexose-6-phosphates, °517-518 and hormones, °701 and insulin, 115-121 of islets of Langerhans, °765 and palmitate,

and temperature, *295 and temperature, *295
and pancreatectomy, 179-182
peripheral, in glucose, glucose-insulin, and insulin sensitivity
test, *134-135, *135
and phenethylbiguanide, *520
and phospholipase-C, *229
and renal insufficiency, *229
and substanceus, adipose tissue.

subcutaneous adipose tissue, and 808-809

glycogen, *532 and growth hormone, 905-909 and dexamethasone study, *135-136 and hypoglycemia, 320-322 and insulin, *915

insulin and albumin, 835-837

deficiency, 451-455 insulin-I-131, in mice, 336-341

and deferoxamine test, *369 of islets of Langerhans, *137 and alloxan-diabetic acidosis, 423-429

MICE

ele

of i

ligh

al

o

of 1

of p

of s

MINE

calci

and :

MITO

MONO

MORP

MORT

of all

and and and

an

and o and d

and d

and

and :

trans

an

an

of

of and

lipids and carbohydrates, °702 and glucagon, 740-746, °917 and hypophysectomy, °609-610 lipids and glucose

and growth hormone, *517 liver acetate and fat mobilization, 346-349

nerve and diabetes, 696-698 and diabetes, 696-698 and obesity, 399, *844 perfused rat liver and insulin, *767 and pregnancy, *435 and ruminants, 326, 335

and lipogenic defect, *533-534 and starvation, 798-809 and sulfonylureas, 363 tricarboxylic acid cycle, *844

triglyceride and free fatty acid and insulin, *137 zinc

and diabetes, *914-915

METALS binding in yeast, *704 chromium and glucose tolerance,
*846 *539-540, and insulin action, 649

METFORMIN -chlorpropamide therapy, *64

METHIONINE and growth hormone, *67

METHOPYRONE and free fatty acids, *366

METHYLGLUCOSE and glucose uptake, *65

3-METHYLGLUCOSE and muscle permeability, *292, *516

1-METHYL-2-MERCAPTOIMIDAZOLE and insulin-I-131 incorporation, 439

MICROANGIOPATHY and diabetic control, *293 of digestive tract, *913 and glomerulosclerosis, 63 and insulin action, 648 deficiency, *292 of intestinal tract, 93-96 and tumoriform muscular degenera-tion, *134

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142

March, 143-232 April, 233-302

May, 303-372

June, 373-442 July, 443-554

September, 623-708 October, 709-774

November, 775-854 December, 855-920

August, 555-622

MICROSCOPY

423-

40,

16

LE

38-

ra-

electron and aortic lipidosis study, 159, 178 and atherosclerotic lesions, 8, 114, and blood vessels of skin in diabetics, 233-250

and diabetic glomerulosclerosis, 61-63

forearm skin capillary study, 252-256

and glomerular lesions, *547 and glomerulosclerosis in alloxan-diabetic monkey, 258-261 and pancreatic islets of rats, 823-828 of skin in lipoatrophic diabetes, 264, 265, 266

of islets of Langerhans, 482-488, 587-592

light

and blood vessels in diabetics, *293-294

of pancreas of rabbits immunized with insulin, 582-583 of liver tissue in sulfonylurea study,

273 of pancreatic tissues

betes, 353

of diabetic tree shrews, 328-329 of mice, 207-210 and postmortem study of the diabetic with Sheehan's syndrome, 75of skin and liver in lipoatrophic dia-

MINERALS

calcium and citrate metabolism, *845 and corticotropin-induced lipolysis, *841-842 and insulin release, 911 and lipolysis, *914 and insulin action, 649

MITOCHONDRION and insulin action, 641

MONOSACCHARIDES transport, and insulin, 377

MORPHINE and glucose utilization, *68

MORTALITY of alloxan-diabetic pregnant mice, 200-

201 and amputation, *293 and blind diabetics, *294, *365 and diabetes, *67-68, 161-162, *228, *365-366, *915 and myocardial infarction, *293

and diabetic acidosis, 694 and diabetic angiopathy, *437 and diabetic coma, 714, 718 and diabetic pregnancy, 830, 831 of diabetic with Sheehan's syndrome, 73-77

and diet-induced diabetes in sand rats, 106, 108, 110, 111 fetal, *370

and guinea pig anti-insulin serum, 669, 672

and infant hypoglycemia, *846 in insulin antibody study, 210 and myocardial infarction, *138 and neonatal hypoglycenia, *843 and nialamide and alloxan, 687 and spontaneous diabetes in tree shrews, 327-330

MUSCLE

basement membrane thickening, 233 and diabetes, 323-326

and bound insulin study, *433 Dupuyten's contracture, *547 and exercise

and serum immunoreactive insulin, 838-840

forearm and insulin response, *544 frog sartorius

and insulin, *516

glucose-C-14 incorporation and "bound" insulin, °843-844 and insulin, 631-632 action, 635-636 response, °702 uptake, and "bound" insulin, 657 in lipoatrophic diabetes, 262

potassium exchange and insulin, *292 and synalbumin antagonist, 396

tumoriform focal degeneration and diabetes, *134 water and electrolyte and insulin, *769

MYOCARDIUM

and alcohol, 578 of diabetic tree shrews, 328 free fatty acid metabolism, *292 infarction, 566

and carbohydrate intolerance, 215-216, 218 and diabetes, °293 in long-standing diabetes, 278 and lower extremity amputation,

*293 and plasma free fatty acids and glu-cose tolerance, *294

cose tolerance, *
and plasma insulin, *68 and potassium, glucose and insulin, *139

in skin capillary study, 253 ischemia and diabetes, *845

NECROBIOSIS LIPOIDICA, *61 and glucose tolerance test, *368

NEPHRECTOMY and insulin distribution, 631-632

NEPHROPATHY

in blood vessels of skin study, 243 in lipoatrophic diabetes, 351-355 and myocardial infarction, *293 and prediabetes, 880 in skin capillary study, 252

NEPHROPATHY, DIABETIC and proteinuria, *435

NEPHROTIC SYNDROME and diabetic glomerulosclerosis, 61-63

NERVOUS SYSTEM

autonomic and impotency, *537-538 and cerebrospinal fluid lipids in diabetes, 471-474 and hyperglycemia, 760 and hypoglycemia, *843 and insulin secretion, *522 metabolism and diabetes, 696-698 peripheral

and diabetes, *437 in juvenile diabetes study, 411-418 and sex, 507-510 phrenicectomy

and protein synthesis, *701 and Schwann-cell abnormalities, *295 sciatic nerves of rabbits and lipogenic defect, *533-534 vagus nerve

and insulin release, *536

NEUROPATHY and diabetic feet, *543 in diabetics and nondiabetics, *368 and impotency, *537-538 and impotency, *537-538 and lipoatrophic diabetes, 351-355 and sex, 507-510 in skin capillary study, 252

NEUROPATHY, DIABETIC and bladder, °525 and cerebrospinal fluid lipids study,

471-474 and diabetic angiopathy, °228 irreversibility, °136 in juvenile diabetes study, 411-418 and osteopathy, °534-535

peripheral and vascular responses, *848-849 and Schwann-cell abnormalities, *295

and skeletal muscle blood-flow study, 323 and vesical dysfunction, *609 visceral, 93-96

NIALAMIDE

and diabetes prevention in rats, 686-689

NITROGEN

and protein-calorie deficiency study, 81

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72

February, 73-142 March, 143-232 April, 233-302

May, 303-372

June, 373-442 July, 443-554 August, 555-622 September, 623-708

October, 709-774 November, 775-854 December, 855-920

NORADRENALINE and pancreatic islet tissue, *137

NOREPINEPHRINE and adipose tissue metabolism study, •64 and insulin, •543, 629

NUCLEOTIDES uridine, and hydrocortisone-induced di-abetes, *436

NUTRITION and deoxyglucose response, °434 and diabetes, 15-16, 17, °528 and "long-acting carbohydrate," °527 and neuropathy, 471 poor and hypermetabolism, 470, 496 and protein-calorie deficiency, 78-88

0

OBESITY and calorie intake, 893 and diabetes, 15-16, 373, *915 with Achard-Thiers syndrome, *436 and exercise, 839 and gout, *918 in mice, *435 in mice, onset, 419 onset, 419
and diabetic pregnancy, 726-728
screening, *366
and starvation, 798-809
survey, *369
and thyroid disorders, *68-69 and diet, 399, 405 and free fatty acids, *366 and glucagon, 860 and glucagon, 860 and glucose and acetate metabolism in rats, *611 tolerance and fasting, *438 tolerance tests, *438 utilization, *915-916 and glycogen reserves, *530 and hyperglycemia and "bound" and crystalline insulin, *610 and hyperinsulinemia, 303, 504 and hyposomatotropinemia, 505 hypothalamic and endocrine glands, 465, 491 and insulin reserve, *529-530 resistance, *226 response, 627, 630-631, 867-873 secretion, 571 and nicotinic acid, *914 and sex, 507-510 and skin capillary study, 251, 252 and starvation, *526-527, *527 and metabolism, *844 and sulfonylureas, *69 and tolbutamide and glucose study, °433

and urine insulin-like activity, *524

OCTANOATE and glucose production and utilization, *369

ORAL HYPOGLYCEMIC AGENTS. See also Sulfonylureas also Sulfonylureas and dosage errors, *526 and glucose metabolism, *520 glycodiazine, *530-531 and insulin resistance, *140 and pregnancy, *532 and serum lipids, *536-537 and starvation, *538 and surgery for diabetics, *66 and triamcinolone-glucose triamcinolone-glucose tolerance test, 726-728

ORNITHINE and insulin, 7

OSMOLALITY and insulin action, 648

OSTEITIS and diabetes, *534

OSTEOARTHRITIS, *534

OSTEOMYELITIS, 351 and diabetes, *534

OSTEOPATHY and diabetes, *543

OUABAIN and insulin and muscle potassium ex-change, *292

OXALACETATE and glucose formation, 19-22 and insulin release, 630

OXFORD, ENGLAND diabetes survey, *849

and congenital malformations, 199-202 consumption and heart disease in infants, 470, 496 of pancreatic islets, *366 uptake in kwashiorkor, *255

OXYTOCIN and muscle permeability to sugar, *516

PALMITATE, 389 and fatty acid incorporation, 445-446 and protein synthesis, *516-517

PALMITATE-I-C-14 metabolism, *295

PANCREAS

alpha-cell tumor and diabetes, 709-712 alterations, and hemochromatosis, *513

beta cells degranulation, *917 and diet-induced diabetes, 108, and insulin, 123 and insulin, 123
fine structure study, *916
granulation in alloxan-diabetic hamsters, 51-57
and growth hormone, 40
and hypothalamic obesity, 465, 491 and insulin storage, 283 synthesis, 624-625 synthesis, storage and release, 281 tumors, 504 capillaries in diabetics and nondiabetics, *434

in

pe

pre

in

rac

rat

res

ane

and

and

and

and

PANO

and

and

PANC

and

-sec

and

and

enla

urat

PEDA

PENT

PEPTI

PERC.

PERIC

PERT

PHAC

and

and

and

desa

and

and

a

a

PANE

PARC

PAN

carcinoma and glucagon secretion, 504 and hypoglycemia, *436 and chelating agents, 44-50

of diabetic hamster, 331 ducts, blood vessels, and islets of Langerhans, 482-483 endocrine

and growth hormone, 30-42 fetal rat and

glucagon-induced insulin re-lease, *918 lease, *918 homografting, *292 in diabetic hamsters, 51-57 and insulin activity assays, *702 insulin

in diabetic Chinese hamsters, *523-524

524
infusion, and blood glucose, 123-125
in insulin-injected cows, 586-592
release, *521-522
and glucagon, *370
and L-leucine, 223
in pregnancy, *140

secretion and diazoxide, *435 and secretin, *845-846 islets

adenoma, 321, *847 and adrenalin study, *137 carcinoma, 143-148 and diabetic with Sheehan's syndrome, 75-76 electron microscopy study, 823and

828 and epinephrine, 571 and glucose infusions, *515 and "hyperglycemic priming," 306 and hypoglycemia, 1, 3 insulin antibody-injected mice, 205-211 and neoplasms, *136

oxygen consumption study, *366 tumors, *295 and benzothiadiazines, *765 lesions, *913

and leucine stimulation of insulin release, 560-564 and nialamide study, 687, 688-689

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 February, 73-142 October, 709-774 June, 373-442 March, 143-232 November, 775-854 July, 443-554 April, 233-302 August, 555-622 December, 855-920

in panhypopituitary and diabetic patient, 420-421 perfused rat and insulin secretion control, *521, 910-912 and calorie deficiency, 78 and insulin immunoassays, 342-345 in rabbits immunized with insulin, 580, 581-584 radioautographic study in mice, 481-487

108,

ham-

491

, 281

•434

Lan-

02

•523-

3-125

syn-823-

306

mice.

n re-

19

86

19.

rat and insulin secretion study, *767 section in hypoglycemia, *138 resection in hypoglycemia, and sulfonylureas, 597-602

PANCREATECTOMY and adrenalectomy, 373 and fatty acid synthesis, and insulin, *291 and glucose metabolism studies, 179-182 and lipid metabolism and hypophysectomy, *609-610

PANCREATITIS and glomerulosclerosis, *703 and plasma insulin, *227 and tolbutamide and glucose tolerance tests, 215

PANCREOZYMIN and glucose tolerance, 556 -secretin infusion test, 94

PANHYPOPITUITARISM and insulin release study, *516

PAROTID GLAND and diabetes, *367, *847 enlargement and hypoglycemia, *769 and insulin-edema syndrome, *849 and hyperketonemia, *539

PEDAL ANGIOGRAPHY, *525

PENTOSE PHOSPHATE CYCLE and glucose oxidation in squid axon, *67

PEPTIDES desamide, 875-878 and gluconeogenesis, 500-505

PERCHLORATE and insulin-I-131 incorporation, *438-439

PERICYTE and basement membrane thickening, *513

PERTUSSIS VACCINE, 671-672

PHAGOCYTOSIS and diabetes, *915 **PHENETHYLBIGUANIDE**

and glucose kinetics, 173-177 metabolism, *520 and insulin release, 630

tolbutamide and glucose response, *764

PHENFORMIN, *136 and chlorpropamide and obese diabetics, *915 and diabetes control study, "610-611 and diabetic pregnancy, 726 and glucose, cholesterol and uric acid responses, "544-545"

PHENFORMIN HYDROCHLORIDE and chlorpropamide therapy, *135 and serum lipids, *536-537

PHENOTHIAZINES and carbohydrate metabolism, 171-172 and glucose metabolism, 102-103

PHENOXYBENZAMINE, 347

PHENTOLAMINE, 347 and insulin and free fatty acids, 629 and insulin release, 627

PHENYLALANINE and growth hormone, *67 and insulin, 7

PHLORETIN and glucose uptake study, *65

and fructose absorption, *226 and glucose, *65, 502 and sugar transport, *365

PHOSPHOENOLPYRUVATE CARB-OXYKINASE, 19

PHOSPHOFRUCTOKINASE and lipoatrophic diabetes, 267

PHOSPHOLIPASE-C and glucose and amino acid metabolism, *294 and lipolysis, *294, 635

PHOSPHOLIPIDS and carbohydrates, *64 and dietary fat, 722, 729

PHOSPHORUS and glomerular basement membrane, *512 and hypocalcemia and hypomagnesiemia, 739, 748

in hyperadrenocorticism, 29

PHOSPHORYLATION and glucokinase, 636-637 and lipoatrophic diabetes, 355

PHOTOCOAGULATION, *701

PIMA INDIANS and diabetes, *527-528

PITUITARY GLAND ablation, *367 and retinopathy, 133 anterior

pancreatrophic principle, °913 congenital absence of, °70 of diabetic tree shrew, 329 and diazoxide-induced diabetes, 319-322

disease and growth hormone secretion, 505 fetal, *295 function

in thyrotoxicosis, *916 and glucose metabolism, protein syn-thesis, and insulin, 115-121 growth hormone and blood sugar changes, *436

hormones and diabetes, *609 and insulin action, 642 insufficiency and diabetes, 73-77, 419-422 irradiation, *367

tumors and growth hormone secretion, *844

PLACENTA and glucose uptake and insulin transfer, °534
and growth hormone, °610
transfer to fetus, °435

insulin-I-131 transfer, *768 lactogen in diabetic pregnancy, *226 and insulin action, 643 and insulin release, 630

and insulin response, 627 prolactin, *846

PLASMA albumin and siblings of diabetic children, 402-403

and synalbumin antagonist separa-tion, *535-536

amino acid and diabetes, *544 and insulin, 5-7 and protein, 304, 305 assays, *914

catecholamines, adrenocorticosteroids and growth hormone, 307 fatty acids, sugar and insulin and carbohydrates, *439

free fatty acids and amino acids, 627 and amino acids, 627 and diabetes, arteriosclerosis, and obesity, °366 and diabetic Chinese hamsters, °534 and diazoxide, 143-144 and epinephrine, 145-146 and glucagon, °917 and hepatic glucose output and glu-cose utilization, °515-516

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 August, 555-622 December, 855-920 April, 233-302

and myocardial infarction, *294 and sulfonylureas, 314-318 gluccse and anti-insulin serum, 445 and free fatty acids, and insulin and diabetes, *609 free fatty acids and triglycerides in glycogen storage disease, 408-409 and glucagon, 124, *434 and insulin deficiency, 452 insulin and lipids and diazoxide, 406-410 and Von Gierke's disease, *841 and insulin response to protein, 303 tests, 775-777 growth hormone *540 and amino acids, *67 and blood glucose, *848 and sex and estrogen, *291-292 human placental lactogen in diabetic pregnancy, *226 insulin, 359-361 assay, *765 assay, *765 and diabetic Chinese hamsters, *523-524 and diet, 105-113 and glucagon, *69 and growth hormone, *439 and arginine, *848 in lipoatrophic diabetes, 263 immunoassay and bioassay correla-tion, *69 tion, °69 insulin antibody and glucose, °847 and intestinal hormones, °701 and intestinal hormones, °701 and kwashiorkor, °225-226 -like activity, °70, °542-543, °914 and chelating agents and mesoxalate, 44-50 and cingulate gyrus stimulation, °610 and myocardial infarctions, *68 and pancreatic diabetes, *227 and poorly regulated diabetes, *291 and reactive hypoglycemia, 1-4 response to glucose and tolbutamide, 867-873 and siblings of diabetic children, 402 ketones and hypoglycemia and diarrhea, *846 lipids and atherogenesis, 126 and glucagon and glucose, *535 glucose and ketones and high-fat diet, *65 in glycogen storage disease, 407 magnesium, 735 nonesterified fatty acids and carbohydrate tolerance, *766-767 proteins and diabetes with Sheehan's syndrome, 74 and zinc fixation, *914-915

sugar and "long-acting carbohydrates,"

*527
testosterone, *537
triglycerides
and diabetes, *843
and insulin, *137
viscosity, *370
vitamin C
and hypoglycemia and hyperglycemia, *228

POLYNESIANS and gout, diabetes and hyperuricemia, *437

POLYNEUROPATHY and cerebrospinal fluid lipids, 473

POLYPEPTIDES diabetogenic, *702 and insulin response, 627

POLYSACCHARIDES aortic, and atherosclerosis and diabetes, *537

POLYURIA and acetone poisoning, 810 and spontaneous diabetes, 327

PORTAL VEIN and insulin secretion, 317

POTASSIUM

and aldosterone production, 643
and epinephrine, °226
exchange
and insulin, °292
exchangeable
and diabetes, °768
flux
and insulin study, °769
and hypokalemia, °842
and insulin release, °226, °521-522,
626, °702, 912
and ketoacidosis therapy, 357
and lipolysis, °914
and myocardial infarction, °138
release
and epinephrine study, °434
replacement
in diabetic acidosis, 694-696

PREDIABETES, 419
and atherogenic diet in rats, *513
and basement membrane thickening,
355
biochemical studies, 880-887
biological study, *518-519
and blood vessel changes, 233-250
and chromosome study, *765
and forearm skin capillary changes,
251-257
and glucose tolerance tests, *518
and hypoglycemia, *847

and insulin response to hyperglycemia, *519 and large infants, *703 and microangiopathy, 648 and phenformin, *544-545 and serum proteins, 331

PREDNISOLONE and lipolysis, *764

PREDNISONE and acetone poisoning, 810 and hypoglycemia, 319 and insulin, 264

betic
and alloxan-diabetic mice, 194-203
and chronic hypoxia
glucose tolerance tests, 130-132
and diabetes
incidence study, 15, 17
onset, 419
among Pima Indians, °527-528
diabetogenic effect
and hypophysectomy, °542
and fasting diet, 399
and gestational blood glucose levels,
466-470
and glucose
movements in uterus, °370
tolerance, °433, °525
and insulin, °848

PREGNANCY. See also Pregnancy, dia-

antibodies in guinea pigs, *768 response, 627, 867 and metabolism and growth hormone transfer to fetus, *435 and placental prolactin, *846 and potential diabetes, *917-918 and serum growth hormone determinations, *292 and tolbutamide response, *140

PREGNANCY, DIABETIC, 830-835
and carbohydrate metabolism, °917
classification of, °532
fetal loss and blood group study, °436
and fetal outcome study, °370
and growth hormone, °610
and insulin, 220-221
and plasma placental lactogen radioimmunoassay, °226
and Sheehan's syndrome, 73
and spontaneous remissions, °766
and sulfonylureas, 269
and triamcinolone glucose tolerance
test, 726-728

PROGESTERONE and carbohydrate metabolism, *913-914

PROLACTINS and free fatty acids, *846 PROPANOLOL

and insulin secretion, 629

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142 March, 143-232 April, 233-302 May, 303-372 June, 373-442 July, 443-554 August, 555-622 September, 623-708 October, 709-774 November, 775-854 December, 855-920 PROT and and and PROT

PRO

-ar

die

and

and

and

ane

and

par

spi

PURO and and and and and

PRUF

PYRU and PYRU and and and upta an

PYRUY and PYRUY incom

QUINI and 2

mina-

PROTEINS -anabolic effect of growth hormone,

carriers of insulin, 815-816 dietary and aortic lipidosis, 178 and insulin response, 303-306 and endocrine control, 78-88 and glucagon, 188

and glucose and hormone release, *918 and insulin and insulin and growth hormones, °67 release, 627, 630-631 and "long-acting" carbohydrate, °527

pancreatic insulin-like effect, 342-345 spinal fluid, 472

and denervation and insulin, *701 and diabetes, 636 and fat absorption, 268 and free fatty acids, *516-517 and insulin, 5, 115-121, *848 deficiency, 443-449 and rat hemidiaphragm, 374

PROTEINURIA, *435 and diabetes with Sheehan's syndrome, 73, 74 and diabetes survey, *227 and retinopathy, *548

PROTEOLYSIS, 637

PRURITIS and glycodiazine study, *140

PUROMYCIN, 377 and beta lipoprotein deficiency, 268 and growth hormone, *136 and insulin and amino acids, *139 and protein synthesis and insulin, 641

PYELONEPHRITIS and diabetes, *525, *610 and vesical dysfunction, *609

PYRIDINE NUCLEOTIDES and insulin deficiency, 451-455

and glycerol-glyceride formation, *526 and hepatic gluconeogenesis, 19-22 and insulin deficiency study, 454-455 uptake by liver and insulin, *767

PYRUVATE-1-C-14 and glucagon study, 190

PYRUVATE-3-C-14 incorporation into blood glucose, *226

QUINETHAZONE and blood glucose, *546 RACE

and diabetes incidence study, 13-14 and diabetic concomitants or complications, 509-510

RADIOACTIVE INDEX, 208-211

RADIOAUTOGRAPHY and insulin-I-125 assay, *533 of pancreatic ducts, 382-386 and tolbutamide and pancreas, 598-600

RESPIRATORY DISTRESS SYN-DROME, 834-835

RETINA circulation, *763-764 microaneurysms, 260

RETINOPATHY
in blood vessels of skin study, 243
and diabetes with Sheehan's syndrome,
74, 75, 76 14, 15, 10 and diabetic control, 497-499 in lipoatrophic diabetes, 351-355 and myocardial infarction, °293 and photocoagulation, °701 in proteinuria study, °435 and sex, 507-510 in skin capillary study, 252

RETINOPATHY, DIABETIC and blindness, *437 classification, *135 classification, "135 and complement levels, 730-733 and growth hormone, "543-544 and hypopituitarism, "66-67, 133 and long-term diabetes, "548 and muscle blood flow, 325 and photocoagulation, "611 and pituitary gland ablation, "367 and prediabetes, 880 and pregnancy, "542 and retinal artery pressure, "702 and trans-sphenoidal hypophysectomy, "66 and urine hydroxyproline, *134 and vitreous contraction, *135

RHEUMATISM and diabetes with Sheehan's syndrome, 73

and insulin release, 630

RICE-MEAL TEST, 901-904

and insulin synthesis, 624 and liver, 639-640 synthesis and actinomycin, 641 and albumin antagonist, 837 and insulin, 377, 635-636, *848 SACCHARIN, 23

SALICYLATES and complement in diabetes, 730-733

SCHIZOPHRENIA in diabetes survey, 97, 164, 165

SECRETIN and blood insulin and glucagon, *845and insulin release, *701, *768

SEIP-LAWRENCE SYNDROME, *69

SERUM albumin

albumin
in antibody response study, *514
and capillary loss in diabetes, *367
and glucose metabolism and insulin
response, 388-398
anti-insulin, 205-206, 349
antibodies, *67
and bound insulin assay, 895
and hyperglycemia, *521
and insulin deficiency studies, 443449, 451-455
in plasma insulin study, 359-360 in plasma insulin study, 359-360 in protein and insulin assay study, 342-345 bicarbonate

and hyperosmolar nonketotic coma, carbohydrate incorporation, *227 cholesterol and cardiovascular lesions, *512-513

and corn oil, 829 and diazoxide, *841 and diet, 888

and diet, 888
and dietary fat, 722, 729
and exercise, 603
and hyperlipemia, *434
chorionic growth hormone-prolactin
and pituitary growth hormone, *292
fatty acids and glycerols
and tablutamide and glycose *433 and tolbutamide and glucose, *433

free fatty acids and diabetes regulation, *291 glucagon-like activity, 709-712 glucose

in diazoxide study, 144 and exercise, 839 and immunoreactive insulin, *515 B-glucuronidase, *848. in growth hormone-induced diabetes, 30-42

hyperlipemic and glucagon, 744-746 hyperosmolarity, °65 immunoreactive insulin and exercise, 838-840 insulin

activity, 285 antagonism, 149-158 bound, °433

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 February, 73-142 March, 143-232 April, 233-302

May, 303-372 June, 373-442 July, 443-554 August, 555-622 September, 623-708 October, 709-774 November, 775-854 December, 855-920

and children of diabetic parents, 882, 883 and cortisone glucose tolerance test, *539 and diabetes with Addison's disease, and diazoxide, 143-144 and epinephrine, 145 and glucagon, °434, °529 and epinephrine, °515 glucose response, °518-519 and growth hormone, 749-757 -induced diabetes, 30-42 and hypertension and vascular disease, °704 and hypoglycemia, °703 with ketosis, 322 immunoreactive, *518, *551 and insulin-like activity, *294 -like activity, 647, *703 and diabetic coma, *548 and kidney disease, *546 and intestinal mucosa study, 555-558 intraperitoneal assay, *369 response to amino acids and sex, *917 and tolbutamide, 663-666 lactescence, 565 lipids and cholesterol crystallization, and dietary carbohydrates, °6 and prediabetes, °519 and tolbutamide, phenformin hydrochloride and NPH Insulin, *536-537 and uric acid and blood sugar cor-relation, *65 magnesium in newborn, 739, 748 phosphate, triglyceride and cortisol and starvation, *533 phosphorus and hyperadrenocorticism, 29 potassium and diabetic acidosis, *843 protein and blood sugar and blood urea nitrogen in cerebrospinal fluid lipids study, 472 and insulin antibodies, *764 augmentation study, *228 insulin-like activity, *69 and lipoatrophic diabetes, 353 and tolbutamide and insulin re-sponse, 331-334 sodium and diabetic coma, 717 synalbumin and prediabetes, 880 triglycerides and diet, 874, 888

and hyperlipemia, *434

and ketoacidosis, 357-358

uric acid

and blood vessel changes in diabetes, 247 and diabetes, *227-228, 507-510 incidence, 12, 14 prevalence among Pima Indians, *527-528 and diabetic mortality, *228 and growth hormone assays, *540 and insulin release, *516 secretion, *291-292 and insulin and growth hormone response to amino acids, *917 and lipid response to diet, *368 and sulfonylureas, *69, 270 SHEEHAN'S SYNDROME, 73-77, 133 and myocardial infarction, *293 blood vessels and diabetes, 233-250, *293-294 capillaries and diabetes, 251-257 -fold thickness and body fat, 725 in glycogen storage disease, 407 hyperpigmentation, in lipoatrophic diabetes patient, 262 in lipoatrophic diabetes, 264, 265, 266, 351-352 and necrobiosis lipoidica, *368, *611 polysaccharides and diabetes, *537

betes patient, 262
in lipoatrophic diabetes, 264, 265
351-352
and necrobiosis lipoidica, *368, *polysaccharides
and diabetes, *537
rashes
and sulfonylureas, 272-273
sensitivity to insulin, 790-796
shin spots and diabetes, *845
xanthomata
and diazoxide, *841

MOKING

SMOKING and serum lipids, blood glucose and platelets, *849

SODIUM and lipolysis, *914

SODIUM BICARBONATE and hyperkalemia, 696 and ketoacidosis therapy, 357 in lactate metabolism in diabetic acidosis, 423

SODIUM THYROXINE, *542

SOMATOTROPIN and insulin release, 630

SORBITOL and alcohol, 578 and diabetic kidney, *517

SORBITOL PATHWAY, *918

SOUTH AFRICANS diabetic, and capillary study, *513 SPINAL CORD and insulin sensitivity, *844

SPINE

hyperostosis and diabetes and acromegaly, *916 SPLEEN

PLEEN
in glycogen storage disease, 407
and insulin-I-131 metabolism, 338, 339
of insulin-injected cows, 593
lesions, *913

gh

gh

gly

gro

her

he

hyj

hy

hy

ins

ins

inte

juv

kid

lact

mo

per

pla

STARVATION
and blood glucose level, °533
and blood sugar levels, °370
and diabetes, °530
diagnosis and therapy, °538
and free fatty acids, 346
and glucose tolerance in obese patients, °438
and hypoglycemia, 1
and insulin
activity, °69-70
response to glucose, 627
and ketoacidosis, 504
and ketone bodies and free fatty acid, °136
and ketosis, °66, °526-527
and obese diabetics, °527
and obesity and metabolism, °844
in pre-insulin era, 277
and uric acid excretion, 358
and weight reduction, 399, 405

STATISTICS
albumin and insulin antagonism, 374376
alloxan diabetes and cholesterol flux into aorta, 605-607
alloxan-diabetic pregnant mice, 200,
201
basement membrane thickening, *610
blood sugar after total pancreatectomy,
180, 181
bound insulin
assay, 896-898
and insulin uptake, 657-660
cerebrospinal fluid lipids in diabetics
and nondiabetics, 472, 473
complement levels in diabetes, 730-733

diabetes duration and retinopathy, 497, 498 diabetes survey in mental hospital, 165-172 diabetic pregnancy, 831-834 dichloroisoproterenol and liver metabolism, 347, 348 enzyme strip blood glucose tests, 692,

fatty acid and protein synthesis in acute insulin deficiency, 445-448

free fatty acids and liver metabolism, 347-348 gestational blood glucose levels, 467,

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

 January, 1-72
 May, 303-372
 September, 623-708

 February, 73-142
 June, 373-442
 October, 709-774

 March, 143-232
 July, 443-554
 November, 775-854

 April, 233-302
 August, 555-622
 December, 855-920

glucagon and insulin and glucose, 857-864 and lipids and urea, 743-745 glucose loading and glucose dynamics study, 779-788 tolerance
and blood glucose in pancreatic
A-cell tumor patient, 710
and high-dose test, *541
and large infants, *702-703
glycogen synthesis and insulin and glucose, 494-495 growth hormone and insulin secretion, serum glucose and fatty acids, 751-757 glucose phosphotransferases, 476-478 hexoses, epinephrine and glucagon and insulin response, 572-575 hyperketonemia and medium-chain triglyceride, 723-724 hyperlipemia and diabetes, 675-677 hyperosmolar nonketotic coma, 715, insulin antagonism assay, 382-386 deficiency and metabolism, 452-454 and glucose uptake in rat adipose tissue, 431
and growth hormone, 926-928
immunity study, 813-820
-induced hyperglycemia, 309-312
release and intested mucosa extract, 556, 557 response to glucose, *704 to protein, 304-306 secretion, 626-629 and diazoxide and tolbutamide, *523 and starvation, 799-804 insulin-I-131 metabolism in mice, 337-339 interrelations of glucose, free fatty acids and insulin, *528 juvenile diabetes and Regular insulin, *550-551 kidneys and insulin disposal, 682-684 lactate metabolism in alloxan diabetic acidosis, 426, 427 leucine and hypoglycemia, 561, 562 lipoprotein lipase in diabetics, 566-568 magnesium deficiency and carbohy-drate metabolism, 735-738 mortality and insulin antibodies in guinea pigs, 669
peripheral neuropathy in juvenile diabetics, 412-416 plasma glucose determinations, 775-777 insulin responses to glucose and tol-butamide, 869-872

lipid tests and epinephrine and glucagon tolerance tests in glycogen storage disease, 407,

408

916

339

nts,

eid,

in-00,

10

ny.

ics

33

97,

al,

b-2,

in 5-

m,

7,

prediabetes, 883-886
proteins and insulin assay systems, 343, 344
radioactive index and mitotic index in pancreas after tolbutamide injections, 600
rat serum bound insulin, 890-892
reproducibility of glucose tolerance test and rice-meal test, 902-903
serum
insulin study, 360, 361
proteins of diabetic and nondiabetic hamsters, 333
sex distribution and frequency of diabetic concomitants or complications, 508, 509
skeletal muscle blood flow in diabetes, 323-325
subcutaneous lipomas and insulin injections, 807-809
sulfated insulin and insulin-resistant diabetes, 458-464
sulfonylureas and plasma free fatty acids and blood glucose, 315-317
synalbumin antagonist, 389-396
and family history, 401-404
tolbutamide
and insulin activity, 664-666
tests and glucose tolerance tests compared, 214, 216, 217
uric acid clearance in diabetic keto-acidosis, 358
urine samples of tree shrews, 327

STEROIDS
cortical
and gluconeogenesis, *226
and diabetes, 319-322
with Acard-Thiers syndrome, *436
and growth hormone, *135-136
penetration into squid axon, *67

STEROLS and serum cholesterol, 829

sucrose
and carbohydrate
incorporation, *227
induced hyperlipemia, *433-434
intolerance study, *609
deficiency, *368-369
and insulin response, *702
and lipid response, *368
penetration into squid axon, *67
and plasma fatty acids, sugar and insulin, *439
and serum lipids, *64

SUGAR and insulin secretion, 571-577, 626 and leucine incorporation into insulin,

penetration into muscle and albumin, 396 and insulin, *516 and serum triglycerides, 888

•918

transport and phlorizin and hypertonic saline, *365 in yeast, *704

SULFOBROMOPHTHALEIN, *135

SULFONYLUREAS
and blood glucose, *320, *546
and blood sugar and serum immunoreactive insulin, *551
and diabetic pregnancy, 831
evaluation, *69
in four-year clinical study, 269-275
and hypoglycemia, 362-364
and hypothyroidism, *67
and insulin
activity, 663-666
release, 630
and leucine, 222-223, 560-564
sensitivity, *136
and monoamine-oxidase-inhibitors, *764
and phenformin, *136
and plasma free fatty acids and blood
glucose, 314-318
SURGERY

amputation, *293, 351, *543
cataracts, *846
cervical vagotomy, 627
and diabetes, *66
and insulin secretion, *536
pancreas
homograft
in hamsters, 51-57
of fetal rat pancreas, *292
resection, *138
and panhypopituitarism with diabetes
patient, 420
peritoneoscopy, *709
phrenicetomy, *701
pituitary gland ablation, *367
thyroidectomy, 278
trans-sphenoidal hypophysectomy, *66

SYNALBUMIN INSULIN ANTAGO-NIST, 149-158, 388-398, °514, 647-648, 655-661 and infant hypoglycemia, °546-547 and plasma assays, °914 separation from plasma albumin, °535-536 and siblings of diabetic children, 400-404

SYRINGES incorrectly marked, 193

T

TEMPERATURE and glucose and palmitate metabolism, *295 and insulin destruction, 187 TES-TAPE, 332, *529

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

 January, 1-72
 May, 303-372
 September, 623-708

 February, 73-142
 June, 373-442
 October, 709-774

 March, 143-232
 July, 443-554
 November, 775-854

 April, 233-302
 August, 555-622
 December, 855-920

TESTES of diabetics with gonadal malfunc-tion, *291

TESTOSTERONE and diabetes with Sheehan's syndrome,

THEOPHYLLINE, *294 and 3',5'-AMP, 633

THIAZIDES and blood sugar, *140

THREONINE and growth hormone, *67

THYMIDINE incorporation by beta cells, 211

H-3-THYMIDINE, 481

THYROID and diabetes with Sheehan's syndrome,

disorders and diabetes, *68-69 function

and infants with heart defects, 470, and lipoatrophic diabetes, 353, 354 insulin-I-131 incorporation, °438-439 and lipoatrophic diabetes, 352 and protein-calorie deficiency, 78

THYROIDECTOMY and fatty acid incorporation, *916

THYROTOXICOSIS and guanethedine, *769 and pituitary-adrenal function test, *916

THYROTROPIN and fatty acid release, 347

THYROXIN and insulin action, 630, 643

D-THYROXIN and hyperlipemia, 407-408

TISSUE and ACTH-activated lipolysis, *842 and bound insulin assay, 894-899 of diabetics, *544 and fatty acid release, 346-349 and free fatty acid and epinephrine and glucagon, \$535 and glycerol release, 317 and hormones, *701 and insulin, *369, 632-635 in lipoatrophic diabetes, 262, 266-267, 353, 354 and lipolysis, *764, *765 and lipomas, 807-809 lipoprotein lipase, 677

metabolism and hormones, *139 and nicotinic acid, *64 response to insulin, 632-635 anoxia, 470

anterior pituitary and glucose metabolism and protein synthesis study, 115-121 axoplasm of squid

sugar, steroid, and amino acid pen-etration, °67 and bound insulin and insulin uptake,

655-661 brain and diabetic angiopathy, *437

capillaries and diabetes, 251

Chinese hamster diaphragm and epi-didymal fat pads and glucose metabolism, *523-524 of diabetics

and insulin action, 649 epididymal fat pad insulin-like activity, 360 fatty acid synthesis, *291

fetal pancreas and insulin study, *548-549 fish islet and insulin degradation, 283

frog sartorius muscle and insulin, *516 and insulin d insulin distribution, 631-632 inactivation, 336-341 -sensitivity compared, 121 uptake, and "bound" insulin, °64

liver and hydrocortisone-induced diabe-tes, *436 and metabolism and insulin, *767

magnesium content, 738

and insulin stimulation of RNA and protein synthesis, *848

mouse diaphragm and glycogen formation, 492-495 glycogen metabolism, *532 mouse liver and kidney and insulin-I-125 assay, *533 muscle

and amino acids, *139 and insulin uptake, *540 and protein-calorie deficiency, 84

neural and free fructose, *918 pancreatic

of insulin-injected cows, 586-594 and thiadiazine and insulin release, *765

permeability to 3-methylglucose, *292

and insulin effect on D-glucose-6phosphate and D-lactic acid, rat adipose and bound and crystalline insulin, and

and

and

and

and and re

re

and

and

and

and

load

and

in p

and

and

and

and

respo

and

in

lip

pr

an

tests

and

toler

an

an

an

an

and '

and

TOXE

TRANY

TRIAM

TRIAM

TRICH

TRICH

and d TRIGL

and and h

and 1

-gluc

an

toler

and glycerol outflow and beta-hy-droxybutyric acid, *433 and insulin effect on adenosine 3',5'-monophosphate, *433 and insulin action and age, 430-431 and insulin and insulin antibody,

*291 rat diaphragm albumin and insulin antagonism, 373-

378 and free fatty acids and protein synthesis, *516-517 glucose metabolism and insulin re-

sponse, 388-398 magnesium deficiency study, 735-738

and protein synthesis, *701 rat epididymal fat pad and bound insulin assay, 894-899 insulin response, and chromium,

rat fat cells and growth hormone, *135-136

rat heart metabolism and temperature, *295 rat hemidiaphragm

th hemidiaphragm and albumin study, °542-543 and bound insulin, 889-892 and insulin uptake, °513-514 and glucose uptake and albumin study, °540-541 and insulin antagonism assay, 380-

386

and pancreatic proteins, 342-345 rat hemidiaphragms and epididymal fat

pads glucose uptake and diazoxide and chlorothiazide, *365 glucose uptake and synalbumin in-

sulin antagonist, 149-158 rat liver

and glucagon and gluconeogenesis, 188-192, *439 and insulin, 183-187

and insulin degradation study, *916 and glucose consumption, *701

TOLAZAMIDE and blood sugar and serum immuno-reactive insulin, *551

TOLBUTAMIDE and acromegaly, *365 and blood sugar and glucose tolerance, *542 and serum immunoreactive insulin, *551 and cerebrospinal fluid lipids study, 473

and diazoxide, *435 in four-year clinical study, 269-275

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 September, 623-708 May, 303-372 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 April, 233-302 August, 555-622 December, 855-920

and free fatty acids and glycerol re-lease, 314-318 and glycose tolerance study, °65 and glycodiazine compared, °140 and heart disease, °68 and hypoglycemia, 362-364 and insulin and insulin release, 560-564, 625 and obesity, °915 response, 867-873 secretion, °523, °545-546, °767 and islets of Langerhans, 597-602 and L-leucine, 560-564 and L-leucine, 222-223 and lipoatrophic diabetes study, 264 leading, 279-280 loading, 279-280 loading, 279-280 and obese patients, *433 in pancreatic homograft study in ham-sters, 51-57 and pancreatic insulin, 630 and plasma free fatty acids, *366 and pregnancy, *140 and renal glucose reabsorption, 90-92 response and phenethylbiguanide, *764 and serum insulin, 663-666 lipids, *536-537 proteins, 331-334 tests and diabetic pregnancy, 727-728 in hypoglycemia study, 2 and thyroid function, °67 tolerance and hyperadrenocorticism, 25 and prediabetes, *519 and starvation, 801-804 tolerance tests and children of diabetic parents, 885, 886 and glucose tolerance test compared, 212-218 and weight gain, *437

in, y-

5'-

31

ły,

3-

n-

re-

ly,

m,

5

in

0-

at

nd

n-

2,

16

0-

11-

y,

TOXEMIA and diabetic pregnancy, 832

TRANYLCYPROMANINE and hypoglycemia, *764

TRIAMCINOLONE -glucose tolerance test and oral hypoglycemic agents, 726-

TRIAMTERENE, *550

TRICHLORACETIC ACID-ETHANOL,

TRICHLORMETHIAZIDE and diazoxide therapy, 144

TRIGLYCERIDES and diabetes, *437 and high-carbohydrate diet, 631

and ethyl chlorphenoxyisobutyrate study, *64 and hormones, 347 and hyperketonemia, 723-724 and hyperlipemia study, 675-678 and lipoprotein lipase study, 465-468 metabolism and insulin, *137 and phenformin, *611

TRYPSIN insulin-like effect, 342-345

TUMORS beta-cell and hyperinsulinemia, 504 in diabetics, 134 and growth hormone secretion, *844 and hormones and induced diabetes, *609 and hypoglycemia, *70, *135, 264, *701 of hypophysis and growth hormone secretion, 504 insulin-secreting and hypoglycemia, 1, 2 intracranial in panhypopituitarism and diabetes case study, 420 islet-cell and benzothiadiazines, *765 pancreatic, *847 and diabetes, 709-712

retroperitoneal mesothelioma and hypoglycemia, *294-295 **TWINS** and diabetes, *70

U

and glucagon secretion, 504

ULCER duodenal and hyperlipemia patient, *433 foot and diabetes with Sheehan's syndrome, 73 and fasting diet, 399 trophic, *534

UNITED STATES and diabetes, 16-17, 97

excretion and hyperketonemia, *539

UREA and 2-deoxyglucose study, *434 formation and glucagon, 740-746 production and growth hormone, *517 and hyperglycemia, 189 and insulin, *767

UREMIA and carbohydrate metabolism, *320 and diabetes with Sheehan's syndrome, 73 and insulin metabolism, *138

URIDINE COMPOUNDS and hydrocortisone-induced diabetes,

*436

URINARY TRACT and neurogenic vesical dysfunction, *609

URINE acetone and acetone poisoning case, 810 and B-hydroxybutyric acid, 723-724 catecholamines and blood glucose, *848 17-OH-corticoid in poorly regulated diabetes, *291 corticosteroids

and protein-calorie deficiency, 81 glucose and acetone, 328 and insulin antibody study, 207 and juvenile diabetes, *550 tests, 127-129, 206, 332, 333, 334 and diabetic Chinese hamsters, *534

in sulfated insulin study, 457-465 haptoglobins and isoagglutins in proteinuria study, *435 17-hydrocorticosteroids and diazoxide, 320-321 and 17-ketosteroids, 24 hydroxyproline, *134

insulin and diabetic and normal children, *848 17-ketosteroids

and impotent diabetics, *537 nitrogen and starvation, *533 protein insulin-like activity, *524 and pyelonephritis study, *610

and carbohydrate intolerance study, *609 and diabetes survey, 164-170 and tolbutamide study, 90-92

tests, 327 in diet study of sand rats, 107 in glomerulosclerosis study, 261 and home management, *526 and hyperosmolar nonketotic coma, 714-720

in juvenile diabetes study, 412 and lactate metabolism in diabetic acidosis, 424-425
in lipoatrophic diabetes patient, 263
in panhypopituitarism with diabetes, 419-420
in severe diabetes, 221

in sulfonylurea study, 270 survey, *529 survey, uric acid and ketoacidosis, 357-358

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE January, 1-72 September, 623-708 May. 303-372 February, 73-142 June, 373-442 October, 709-774 March, 143-232 July, 443-554 November, 775-854 April, 233-302 August, 555-622 December, 855-920

URISTIX, 424

URUGUAY glucose tolerance, nutrition, and diabetes in, 9-17

UTERUS rat, and glycogen synthetase, *769

V

VAGUS NERVE stimulation, and insulin secretion, *522

VALINE and growth hormone, *67

VALINE-C-14 incorporation into protein, 911

VALLANCE-OWEN INSULIN ANTAG-ONIST, 149-158

VASCULAR DISEASE
and diabetes, °65-66, °292-293, °436
and diabetic osteopathy, °534-535
and myocardial infarction, °293
and panhypopituitarism with diabetes,
419-422
and serum insulin, °704
and serum lipids, °536-537
and triamcinolone glucose tolerance
test, 726-728

VASCULAR SYSTEM
capillaries
and prediabetes, 880
lesions
and diabetes, °703
and leucine, 560-564
peripheral
and diabetic neuropathy, °848-849
and retina, °763-764

VASOPRESSIN and 3',5'-AMP, 633, 642

VEINS
pancreatic
and chelating agents, 44-50
and insulin release, *536
portal
and hyperglycemia, *532-533

VENEZUELA glucose tolerance, nutrition, and diabetes in, 9-17

VOMITING in panhypopituitarism with diabetes, 419

VON GIERKE'S DISEASE and diazoxide, 406-410, °841 and endogenous glucose production, °519-520 and glucagon and epinephrine, °529 and glucose infusion, °434

W

WEIGHT. See also Obesity
of alloxan-diabetic pregnant mice, 197199
in diabetes incidence study, 11-12, 13,
14, 15-16
and diabetes survey, 169-170
and diet-induced diabetes, 112
gain
in alloxan-diabetic monkeys, 261
and calorie intake study, 893, 900
and magnesium deficiency, 735
and hypothalamic lesions, 465, 491

and maternal gestational blood glucose levels, 466-470
loss.
and diet, 399, 405
and phenformin, °610-611
and sulfonylureas, °64
of mental patients in diabetes survey, 98, 103
of patients in sulfonylurea study, 270, 272, 274

reduction
and hormones, 505
of tree shrews in spontaneous diabetes
study, 327
and triglycerides, *437

\mathbf{X}

Abran

Abran

Abran

Adam

Adam

Albert

Albrin

Alexar

Alger, Alp, I

Amara

Anazi.

Ander

Ander

Ander

Andre

Anger

Anselr Antar,

Antoni

Arky, *76

Arnold Arnott Arnou Arora, Arquil Asherd Ashmo Assan, Ayala, Azarno

Bagda Baig, I Bajusz Balash Balasse Baluda Bank, S Barbac Barker Barnet

514, 889

XANTHINES, 633

of infants

XANTHOMATA and diazoxide, *841 in glycogen storage disease, 407 and hyperlipemia, 675

XENON-133 and skeletal muscle blood flow study, 323-326

XYLITOL, *140

D-XYLOSE absorption test, 262-263 and insulin secretion, 571 transport, 377 and albumin, 389

 \mathbf{Z}

ZINC and insulin secretion, 630

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

 January, 1-72
 May, 303-372
 September, 623-708

 February, 73-142
 June, 373-442
 October, 709-774

 March, 143-232
 July, 443-554
 November, 775-854

 April, 233-302
 August, 555-622
 December, 855-920

AUTHOR INDEX 1966

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1966. Entries marked with an asterisk (*) indicate authors of material that appeared in the Abstracts only. The Subject Index appears on page 1.

glu-

vey,

270,

etes

udy,

Abrams, C. L., *846
Abrams, M. E., *844
Abramson, Eugene, *843
Adams, Levi C., *533-534
Adams, Peter A. J., *917
Alberti, K. G. M., *225
Albrink, Margaret J., *226, *439, *843
Alexander, Ralph W., 362-364
Alger, Carlos R., 726-729
Alp, Haluk, *609
Amaral, Jose A. P., 675-679
Anazi, Moritoshi, *140
Anderson, D. E., *140
Anderson, J. M., *843
Anderson, John, *365
Andres, Reubin, *539
Angervall, L., *134, *913
Anselmino, K. J., 913
Anselmino, K. J., 913
Antar, Mohamed A., *64
Antoniades, Harry N., *64, *433, *513-514, *610, 655-662, *766, *843-844, 889-893
Arly, Ronald A., *70, *137, 567-570, 889-893
Arky, Ronald A., *70, *137, 567-570, *769, *843
Arnold, R., *917
Arnott, James H., 457-465
Arnould, Y., *138, *915-916
Arora, Ravindra S., 279-280
Arquilla, Edward R., *523, *763
Ashcroft, George, *764
Ashmore, J., 346-350, *517
Assan, R., *139, *229
Ayala, Luis Castelazo, 726-729
Azarnoff, Daniel L., *64

Bagdade, John D., *524 Baig, H. A., *225-226 Bajusz, G., *228 Balash, W. R., *70 Balasse, E., *915-916 Baluda, Maryellen C., *844 Bank, S., *227 Barhaccia, I. 173, 179 Barbaccia, J., 173-178 Barker, Barbara, 515-516 Barnett, Carol A., *365

Barr, Glenn A., *64
Barron, Edward J., 423-429
Barry, J. M., *848
Bassett, J. M., *439
Bastenie, P. A., *436, *915-916
Bates, Robert W., *609
Beaser, Samuel B., 51-58, *702
Beck, J. C., *532-533, 555-559, *845-846
Beck, Lyle V., 336-341, *533, 680-685
Beck, Paul, *226, *365, *844
Begneaud, Wallace P., *702-703
Behrman, Simon, *763-764
Beigelman, Paul M., *291
Belknap, Benjamin H., 675-679
Bell, E. G., 205-211
Bell, J. J., *846
Belmonte, Mimi M., *529
Benedetti, Andrea, *529
Benedetti, Andrea, *529
Bennett, Leslie L., *521-522, 910-913
Bennett, Mildred J., *609
Bennett, Peter H., *527-528
Benveniste, Daniel, 93-96
Beres, Joseph, *610
Bergen, Stanley S., Ir., 723-725 Benveniste, Daniel, 93-96 Beres, Joseph, °610 Bergen, Stanley S., Jr., 723-725 Berger, Sheldon, 303-306 Berkow, Joseph W., °365 Berns, A. W., °523 Berris, Robert, 419-422 Berris, Robert, 419-422
Berson, Solomon A., 875-879
Beutler, Ernest, *844
Bewsher, P. D., 346-350, *517
Bierman, Edwin L., *524, 675-679
Binder, Christian, 323-326
Bird, G. S., *229
Birenboim, Harold, 1-4
Björntorp, Per, *64, *433
Blackbourne, Brian, 277-278
Blank, H., *438
Blankenbaker, Ronald, *533, 680-68 Blank, H., °438
Blankenbaker, Ronald, °533, 680-685
Blanks, M. C., °534
Bleicher, Sheldon J., °227, 406-410, °914
Blizzard, Robert M., 319-322
Blondheim, S. H., °433
Blumenthal, Herman T., °536, 812-822
Bolinger, Robert E., °291, °524, °844
Bonadonna, Gianni, °134
Bonessi, J. V., °70
Bookman, John J., °532
Booth, Richard W., °252

Borison, H. L., *68
Bosch, Ricardo, 686-690
Boshell, Buris R., 342-345, *529-530
Bottermann, P., *433
Bowen, Angela J., 775-777
Bowman, Roger H., *844
Boyle, Constance, *520-521
Boyns, D. R., *137, *701, *914
Bradley, Edwin M., *539
Bradley, Robert F., *293
Braunsteiner, H., *437
Braverman, Lewis E., *769
Brech, W. J., *530
Breckenridge, A., *704
Breithaupt, David L., 251-257
Brockhurst, Robert J., *701
Brodoff, B. N., *517, *530
Brown, H., 734-739
Brown, Joseph D., 314-318
Brownings, Margaret, *916
Brunjes, S., *537-538
Buchler, Dolores, *914
Bunnag, Sirotma, 597-603
Bunnag, Sirotma, 597-603
Burnch, H. B., *451-456
Burch, Thomas A., *527-528
Burgess, J. A., *516, *848, 905-910, *917, *918
Bürgi, H., *916-917
Burns, Thomas W., *764 Bürgi, H., *916-917 Burns, Thomas W., °764 Buschiazzo, Hector O., 686-690 Buschiazzo, Perla Mordujovich de, 686-Buse, John, 388-399, *516-517, *701 Buse, Maria G., 388-399, *516-517, *701 Butcher, R. W., *433 Butterfield, W. J. H., *134-135, *844 Byron, Richard, 262-268

C

Cahill, George F., Jr., 183-187, 188-193, °294, °369, 475-479, °917 Caird, F. I., °225 Calderón, Rolando, °70, 130-132 Camerini-Davalos, Rafael, °135, °765 Cameron, J. S., °914 Campbell, James, 30-43, °515, 749-758

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 February, 73-142 June, 373-442 October, 709-774 November, 775-854 March, 143-232 July, 443-554 December, 855-920 April, 233-302 August, 555-622

Carey, Robert W., *701 Carlson, L. A., *914 Carnazzo, Anthony J., *525 Carrión, Enrique, *70 Carnazzo, Anthony J., *525 Carrión, Enrique, *70 Carter, S. A., *848-849 Carter, T. M., *528 Casper, Donald J., *433, *913-914 Cates, J. E., *66 Cavalieri, Ralph R., 173-178, *520 Cerasi, Erol, *764, *848 Cavalieri, Ralph R., 173-178, *520
Cerasi, Erol, *764, *848
Cervantes-Amezcua, Alfredo, *135, *765
Cestaric, Edward, *370
Chaikoff, I. L., 438-439
Chakrabarti, R., *844-845
Chapal, J., *137
Chaplin, Hugh, *609
Chen, Chiung Hui, *917
Cheraskin, E., *228
Chernick, Sidney S., *291
Cherry, Richard A., *518-519, 880-888
Chester, Edward M., 307-313
Chiba, Mamoru, *140
Chlouverakis, C., *137
Choi, Young, *530-531
Cibis, Paul A., *611
Clark, B. F., *64-65
Clark, M., *368-369
Clearly, William J., Jr., *918
Cocco, Arthur E., *226, *365
Cochran, Burt, 838-841
Cohen, Aharon M., *433-434
Cohen, Burton D., *520, *547
Cohen, M. Michael, *531
Cohn, Clarence, *845
Cohn, R. E., 507-510
Collin de l'Hortet, G., *229
Collins, Lois C., *543
Colwell, Arthur R., Jr., 123-126, *531, 560-564
Colwell, John A., 123-126, 497-499, *519, 560-564 Colwell, John A., 123-126, 497-499, *519, Colwell, John A., 123-126, 481-136, 531, *531

Comstock, Betty S., *845

Comstock, Eric G., *845

Conard, V., *138, *915-916

Conason, Emil G., 222-224

Conn, Jerome W., *67, *69, *226, 228, *702, *703, *764-765

Constam, G. R., *365-366

Conte, F., *846

Coon, Edmund, *609

Cooper, Alan J., *764

Copp, E. F. F., *517-518

Corley, Charles, *69

Cortazar, Jaime, *531, *546

Costanzi, Guilio, *67

Coyle, Virginia C., *525-526

Craig, J. W., *546

Crampton, Joseph H., *542, 775-777

Creutzfeldt, W., *767

Crevasse, Lamar, *295

Crigler, John F., Jr., *703 *531 Crevasse, Lamar, *295 Crigler, John F., Jr., *703 Crocco, John A., *65 Crockford, Peter M., *434, *845 Crofford, Oscar B., *65, *139 Crout, J. Richard, *523 Csapó, G., *228 Csorba, Thomas R., *609

Culp, Hilman W., *520 Cumming, W. S., *546 Curreri, William P., *848 Cutler, R. E., 357-359 Czyzyk, Artur, *764

П

Dailey, R. E., °764
Dambacher, M., °433
Dandrow, Robert V., °917-918
Danowski, T. S., °70, 507-510, °845
Daughday, William H., °226, °365, °844
Daunas, J., °517, 740-748
Davidson, F., °437
Davidson, J. K., °532
Davidson, Mayer B., 373-379, 380-387, 835-838
Davidson, Paul C. °226, °430, °842 Davidson, Paul C., *226, *439, *843 Davis, Mathew D., *135 DeCaro, Lucio G., *366 Deckert, Torstein, *847 DeCaro, Lucio C., °366
Deckert, Torstein, °847
De Grazia, J., 173-178
Deiss, William P., Jr., 519-520
Dekaban, Anatole, °65
de l'Hortet, Gerard Collin, °703
Della Casa, Luciano, °848
Demartini, F. E., 357-359
Derot, M., °139, °229
Dettwyler, W., °914-915
DeVilliers, Darrell C., Jr., °845
Devlin, James G., 790-797
Dexter, Robert, °69
Di Benedetto, Robert J., °65
DiPlacido, John, °529-530
Ditziel, J., °370
Dixit, Padmakar K., °845
Dobrzanski, Tadeusz, 430-431 Ditzel, J., *370
Dixit, Padmakar K., *845
Dobrzanski, Tadeusz, 430-431
Dobson, Harold L., *543
Doisy, Richard J., *539-540
Dolais, J., *139
Dolger, Henry, *532
Dolkart, R. E., *514
Dollery, C. T., *704
Doupe, J., *848-849
Doyle, F. H., *367
Drachman, Robert H., *915
Drägert, W., *767
Drash, Allan, 319-322
Drouet, J., *139
Drury, M. I., 830-835
Dullin, William E., 331-336, *523-524, *534, *535-536
Duncan, Carfield G., *438
Duncan, L. J. P., *64-65
Dunn, James P., *655
Dunn, James P., *655
Dunn, J., *522, *532-533, 555-559, *768, *845-846
Dürr, F., *227
Dyck, D. R., *541

E

Eberle, Vincent L., *542 Edozien, J. C., *225 Ehrlich, Robert M., 400-405
Eisentraut, A. M., *522-523, *768
Eitzman, Donald, *370
Ellenberg, Max, *524-525, *609
Elliott, Frederic S., *226, *434
Ellis, J. P., *69, *439
Emson, H. E., *135
Engelhardt, Hugo T., *65
Engleson, G., 411-418
Ensinck, John W., *514, *542-543, 623-654
Epstein, Frederick H., *535
Erickson, Ethel E., *436
Estrich, David, *527, *538
Evans, John R., *369-370
Ewing, Carol, 419-422
Eymontt, Michael J., 262-268
Ezdnili, Ediz Z., *522, *701

Fried

Fried

Frohm Fukay Funk, Futter Fyfe,

Gabba Gallov Galton Gamst Garcia Garcia Garcia

Gay, A Gelb,

Gelfan Gellis,

Gener-Genut

Gerrits Gersho *610 Getty, Gibbs, Gibbs, Giebel Gifford Ginos, Giovan Gitelso Gitlin, Giza, T

Gleaso

Glick,

Glinsm Glogne Goetz, Goldne Gomez Goodm Goodm Goodm Goodno Gordor, Gottliel Gottliel Gough, Gourley

Graber, Grapin,

Graef, 1

Grasso, Gray, 1 Greenbe

Greenw Greenw

Gregeri

1

Fabrykant, Maximilian, *135
Faiman, C., *533
Fain, John N., *135-136, *291, *609-610, *701
Fajans, Stefan S., *67, *136, *764
Farber, Leonard, *914
Farese, Genevieve, *67
Fattorini, Ada, *366
Fedeczko, Danuta, 58-60
Federlin, Konrad, *291
Fedynskyi, Nathalie, *533
Felber, J. P., 492-496
Feldman, Robert, 579-585
Felts, J. M., 292
Fensterer, F. S., *540-541
Ferrier, Thomas M., *65-66
Field, James B., *520-521
Field, Richard A., *517, *533-534, *543-544, *610, 696-698, 730-733
Fineberg, S. K., *915
Finn, Jack, *763
Fisher, Cail F., *366, *541, *846
FisteGerald, M. C., *227-228
Flemming, F., *66
Flores, Homero V., 726-729
Floyd, John C., Jr., *67, *764-765
Forbath, Nicholas, *369-370, 778-790
Forman, R., 714-722
Forsham, Peter H., *136, 251-257, *520, 571-578, 579-585
Franckson, J. R. M., *138, *436, *915-916
Frantz, Andrew G., *291-292, *543-544, Fraser, Russell, *294-295, *367, *704
Freda, Vincent J., *436
Freedlender, A. E., *528
Freeman, Betty, 276-277
Freeman, 279-28
Freedander, A. E., *528
Freederici, H. H. R., 233-250

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

 January, 1-72
 May, 303-372
 September, 623-708

 February, 73-142
 June, 373-442
 October, 709-774

 March, 143-232
 July, 443-554
 November, 775-854

 April, 233-302
 August, 555-622
 December, 855-920

Friedman, Bernice, *226 Friedman, Naomi, *434, *701 Froesch, E. R., *916-917 Frohman, Lawrence A., 105-114, *522 Fukayama, George, *527, *538 Funk, H. U., *434 Futterweit, Walter, *226-227 Fyfe, T., *849

623-

610

543--

90

520, 915--544 :

Gabbay, Kenneth H., *517
Galloway, John A., *520
Galton, D. J., *701
Gamstorp, I., 411-418
Garcia, Antonio, 183-187, 188-193
Garcia, M. J., *518
Cay, Andrew J., *702
Gelb, Alvin M., *916
Gelfand, Maxwell L., *135
Gellis, Sydney S., 466-470, 917-918
Gener-Segui, Juan, 894-900
Genuth, Saul M., 798-806
Gerritsen, G. C., 331-336, *523-524, *534
Gershof, Stanley N., *433, *513-514, *610, 655-662, *843-844
Getty, R. E., 327-330
Gibb, B., *434-435
Gilford, H., 258-261
Giebelmann, R., *434-435
Gifford, H., 258-261
Gioson, James Z., *367
Giovannelli, Carlo Alberto, *66
Gitelson, S., 810-811
Gitlin, David, *435
Giza, Tadeusz, 58-60
Gleason, R. E., *518
Glick, Seymour M., *846
Glogner, P., *227
Goetz, Fred C., 5-8, *140
Goldner, Martin G., *914
Gomez-Acero, José, *916
Gonet, Alain E., *292, *435
Goodman, Edward H., Jr., *226
Goodman, Joseph I., *136
Goodner, Charles J., 115-122, 373-379, 380-387, 835-838
Gordon, E. S., *530
Gorini, Maurizio, *366
Goto, Yoshio, *140
Gottlieb, Chester W., *227
Gough, K. R., *66
Gourley, D. R. H., *292
Gousios, A., *292
Graber, Alan L., 143-148, *515
Grapin, A. M., *139
Graef, Irving, 133
Grasso, Sebastiano C., 571-578
Grav, P. A. 277-278 Graef, Irving, 133 Grasso, Sebastiano G., 571-578 Grasso, Sebastiano G., 571-578 Gray, P. A., 277-278 Greenberg, B. Z., *140 Greenough, William B., 846-847 Greenwood, F. C., *367 Gregerman, Robert I., *539

Gregor, W., *514
Gregory, Frederick R., 471-474
Gregory, Raymond L., 471-474
Grenier, N., *139
Grimaldi, Richard D., *525, *534
Grimes, B. J., 507-510
Grodsky, Gerold M., *136, *521-522, *540, 571-578, 579-585, 910-913
Gronberg, Albert, *534-535
Grumbach, Melvin M., *292, *846
Guevara, Lilia B., *524
Gullick, Herbert D., *535
Gundersen, Kare, *551, 663-667
Guntsche, Enrique M., *67, *764-765
Gwinup, Grant, 262-268, 838-841 Gregor, W., *514

H

Hackel, Donald B., 105-114
Haden, B. H., *536
Haist, R. E., *532
Hales, C. N., *68, *764
Halpern, B., *514
Halverstadt, Donald B., *610
Hamlin, Marie, 276-277
Hamwi, George J., 262-268, 526-527, 549
Hansen, Ruth Osterby, *227
Hanson, P. G., *136
Hanley, T., *134
Harbeck, Ronald J., *845
Hardy, Patrick, 279-280
Hare, D., *537-538
Harriman, D. G. F., *136
Harrold, B. P., *66
Hart, William R., *136
Hartroft, W. Stanley, *512-513
Harvey, H. P. B., *437
Hashim, Sami A., 723-725
Haslam, Ruth, *704
Hassan, Tarek, *916
Hatcher, J. D., *229
Havel, R. J., *292
Hayner, Norman S., *535
Hazlewood, Carlton F., *769
Healey, L. A., 357-359
Heard, C. R. C., 78-89
Helgason, Thorir, *228-229
Hellerström, Claes, *366
Helmke, Elizabeth, 691-694
Henderson, John W., *66-67
Hendrix, Thomas R., *226, *365
Henn, Mary J., *917
Hennes, Allen R., 133
Henningsen, Per, 90-92
Henriques, Kathleen J., *520
Herbert, Victor, *227
Herman, J. B., 810-811
Hermandez, Alfredo, 419-422
Herrera, M. Guillermo, *545
Hetenyi, Geza, Jr., *369-370, 778-790
Hill, David, 219-222
Hill, D. W., *367
Hinerman, Dorin L., *136 Hackel, Donald B., 105-114

Hines, R. A., *764
Hirschhom, Norbert, *846-847
Hirschhom, Norbert, *536-537
Hockaday, T. D. R., *293, 366-36'.
Hodges, Robert E., *702
Hoet, J. J., *765
Hoffbrand, B. I., *435
Hoffmann, F., *913
Hogan, Richard A., *514, *542-543
Hogeman, O., *764
Holcomb, George N., *535-536
Holdsworth, C. D., *293
Holland, James F., *701
Hollander, Philip B., *291
Hollfield, Guy, *365
Hollister, Leo E., 691-694
Hollobaugh, Samuel L., *526
Holloszy, John O., *292
Hollm, M. S., *534
Horii, Kin-ichi, 194-204
Horino, Masaharu, 812-822
Hornbrook, K. R., 451-456
Horvath, Steven M., *370
Hoskin, F. C. G., *67
Houareau, M. H., *137
Howell, S. L., *435
Howells, Leonard, 269-275
Huber, Agnes M., *433, *610
Hunton, R. B., *67, *435-436
Hurwitz, David, *766
Hüter, K. A., *438
Hutt, B., *138 *293, 366-367

Imura, Hiroo, *136 Ingalls, Theodore H., 194-204 Irvine, Jane, *532 Ismail, Ahmed A., *367 Ito, Mitsuo, *536

J

Jackson, Ivor, *916 Jackson, R., *513 Jackson, W. P. U., *227, 714-722, *847 James, J. Angell, *66 Jarrett, R. John, *137, *701, *765, *914 Javid, R., *522 Javid, R., *522
Jeanrenaud, Bernard, *139
Jeffrey, E. L., *528
Johnson, Benjamin C., *535
Johnson, L. R., *536
Johnson, R. E., *136
Jones, Ann B., *294
Jones, Don P., *137, 565-570
Joplin, G. F., *367
Jørgensen, Kai R., *847
Joron, G. E., *548
Josimovich, John B., *610
Julkunen, Heljo, *916
Jung, William, *534

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 September, 623-708 May, 303-372 October, 709-774 February, 73-142 June, 373-442 July, 443-554 November, 775-854 March, 143-232 April, 233-302 August, 555-622 December, 855-920

K

Kadish, Arnold H., *536 Kahan, Miles, *536-537 Kahil, M. E., 734-739 Kalant, Norman, *537, 604-608, *609 Kalbfleisch, John M., 9-18, *528 Kalkhoff, R. K., 443-450 Kaneto, Akio, 610 Kaplan, Selna L., *292, *846 Kappeler, H., *765 Karam, John H., 571-578 Karäwa, Risto, *916 Katigbak, Edgardo B., *917 Katsoyannis, Panayotis G., *367 Katigbak, Edgardo B., *917 Katsoyannis, Panayotis G., *367 Katzen, Howard M., *518 Kaufmann, Nathan A., *433-434 Kawashima, Satoshi, *140 Keen, Harry, *137, *701, *765, *914 Keller, P., *227 Kellock, T. D., *66 Kelly, Gerard J., *525 Kent, J. R., *537 Kerr, John H., 212-219 Ketterer, H., *522-523, *768 Kew, M. C., 694-696 Keyes, Frances P., *848 Keyes, Frances P., *848 Khalifa, Kamel, *367 Kilsheimer, G. S., *517 Kim, H. S., *537-538 Kim, On Ja, *513 Kimmelstiel, Paul, 61-63, *610 Kim, On Ja, *513
Kimmelstiel, Paul, 61-63, *610
King, Christine, 336-341
Kinney, T. D., 105-114
Kinsell, Laurance W., *527, *538
Kinsella, Ralph A., Jr., *542
Kipnis, David M., *365, 443-450, *766-767, 867-874
Kirsteins, Lidia, *518-519, 880-888
Kjelsberg, Marcus O., *535
Klassen, G. A., *544
Klein, Joseph P., *916
Klein, Melvyn, *841-842
Knapp, S., *523
Knappe, G., *847
Kneer, P., *767
Knopf, Ralph F., *67, *764-765
Kolb, Felix O., *529
Kopetz, K., *916-917
Kosaka, Kinori, 44-50, 179-182, *610, 901-904 901-904 Koschel, R., *767
Kotchen, Jane M., *917
Kovacev, Vanco P., *135-136
Kovács, K., *228
Krall, Leo P., *849
Krehl, W. A., *702
Kreines, Kenneth, *513, *530-531
Kreisberg, Robert A., 342-345, *529-530
Krosnick, Arthur, *538-539
Kruger, Francisco, 130-132
Kruger, Fred A., 262-268, *526
Krulich, L., *436
Krush, Anne J., *917
Krut, L. H., *140
Kudzma, David J., *539 Koschel, R., *767 Kudzma, David J., *539 Kumate, Jesús, *435

Kuske, Terrence T., *844 Kuzuya, Nobusada, 179-182 Kuzuya, Takeshi, 901-904

L

L
Lacy, Paul E., *609
Lal, F., *294-295
Lambert, A. E., *765
Landon, J., *70
Langman, M. J. S., *66
Langs, Harold M., 319-322, *539
Lanza, Frank L., *436
Larrson, Y. A. A., *703-704
Lascelles, R. G., *295
Lassen, Niels A., 323-326
Lau, Kam-Seng, *227
Lauris, Vilma, 475-479, *545
Lauvaux, J. P., *69, *436
Lawecki, January, *764
Lawrence, R. D., *367, *847
Lazarow, Arnold, 281-289, *845
Lazarus, L., *702
Lazarus, Sydney S., *549
Leadbetter, Guy W., Jr., *610
Lebovitz, H. E., 105-114
Lecocq, Frank R., *539
LeCompte, Philip M., 586-596
Lee, John C., 251-257, 579-585
Lee, Nancy, 471-474
Lefebvre, P., *917
Lein, Allen, 519
Lellouch, J., *139
Lemberg, A., *517
Leonard, Samuel L., *437-438
Leroux, G., *138
Levin, B., *368-369 Lemberg, A., 511
Leonard, Samuel L., *437-438
Levin, B., *368-369
Levin, Fred M., *226, *434
Levine, R., *517, *530, *540, 740-748
Levine, Robert A., *539-540
Lewis, Arthur A., *914
Like, Arthur A., *917
Likly, Beverly F., *917
Limaye, N. R., 507-510
Lindbjerg, Ib F., \$23-326
Lindenbaum, John, *846-847
Linder, Morton, *611
Linfoot, John A., *367, *540
Lippman, H. G., *434-435
Lister, John, *847-848
Little, J. Alick, 457-465
Llerena, Luis A., *70, 130-132
Logan, J. E., 127-129
Logothetopoulos, John, 205-211, 823-829
Logothetopoulos, John, 205-211, 823-829 Logan, J. E., 127-129
Logothetopoulos, John, 205-211, 823-829
Lombard, L. S., 327-330
Lopez-Quijada, Clemente, *916
Loubatieres, A., *137
Louis, Lawrence H., *702
Lowy, C., *439
Lucas, Charles, *69, *228
Luft, R., *764, *848
Lukert, Barbara P., *291
Lund, G. H., *523-524
Lundbaek, Knud, *437
Luntz, George, *387
Lutz, Phyllis G., *228 Luyckx, A., *918 Lynch, Henry T., *917

M

Mertz

Metzg Mever Mialhe Micka

Middle

Middle

Midtg

Mietti Mikat Miki, I Miller, Miller. Miller,

Mills, Milner. Ming, Minick Mirsky. Mirura. Mistry, Mittra Mizel. Mizuno Mobley Moody,

Moore. Moore, Moorho Morales Morgan

Moses, Moss, Ja Most, S Mougin Moulton

Muller, Munck, Munive, Munro, Murchis

Nabarro. Nabwan Nakao, I Naldjian

Narahara

Narduzz

Navarett

Neale, G

Nechemi Nellen, 1 Neubron

Nibbe, A Nielsen, Nielsen,

Niemeye Nikkila, 1 Ninomiya Nishikaw

Norman, Nuttall, I

McAnn, Michael L., *917 McArthur, R. G., *848 McBee, James W., *436 McArthur, R. G., *848
McBee, James W., *436
McCann, Michael L., *917
McCann, S. M., *436
McCarthy, L. E., *68
Macchi, I. A., 51-58, *702
McCracken, John D., *769
McDonald, Glen W., *439, *541, *846
MacDonald, I., *137-138, *227, *368, *765
McGlamery, E. L. Jeffrey, *528
McIntyre, Neil, *293, *370
McIwain, C. L. K., *295
McKendry, J. B. R., *544
Mackenzie, Malcolm S., 307-313
McMahon, Robert E., *520
McMaster, Jan, 388-399, *701
McMillan, Donald E., 251-257
McPhaul, John J., Jr., *539
Madison, Leonard L., *515-516, *848
Madwar, Kasdy R., *367
Maffezzoli, R., *918
Mager, Milton, *67
Mahan, C., *528
Mahan, Clare M., *369, 466-470
Mahler, Richard J., *534, *540-541
Mahmood, Alan S., *846-847
Malaisse, W. J., *138, *436, *521, *915-916
Malins, J. M., *227 916
Malins, J. M., *227
Manchester, K. L., *702
Mancini, Antonio M., *67
Mandel, Emanuel E., *536-537
Marbach, Edward P., 838-841
Marble, Alexander, 135, *292-293, *518
Marcus, Robert, 351-356
Mariani, M. M., *137
Marks, Herbert H., *67-68
Marks, I. N., *227
Marks, James F., 276-277
Marks, Vincent, *69, 855-866
Marri, Germano, *69, 855-866
Martin, Friedelene, *434-435
Martin, Julio M., 359-362, 400-405, *512-916 Martin, Julio M., 359-362, 400-405, *512-513 Martin, S., *434-435 Maruhama, Yoshisuke, *140 Maumenee, A. Edward, °365 Mason, John W., °769 Matos, Otsenre E., °295 Matsuda, Ichiro, 604-608, *609 Mayne, N., *368 Mayne, R., *848 Mayie, R., °446 Medina, Rosa, °703 Meek, Joseph C., °524 Meister, L., °537 Merimee, T. J., °516, °848, 905-910, °917, °918 Merlino, Mario, *134

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

September, 623-708 January, 1-72 May, 303-372 February, 73-142 June, 373-442 October, 709-774 November, 775-854 March, 143-232 July, 443-554 December, 855-920 April, 233-302 August, 555-622

Mertz, Walter, *368, *846
Metzger, R. P., *517-518
Meyer, V., *138
Mialhe, P., *138
Mickal, Abe, *702-703
Middleton, G. D., *223
Middleton, G. G., *225
Midtgaard, Knud, 93-96
Miettinen, Tatu A., *68
Mikat, E., 105-114
Miki, Eishi, *610, *917
Miller, Benjamin F., *848
Miller, Max, *527-528
Miller, Ralph E., *769
Mills, Gordon C., *436, 471-474
Milner, R. D. G., *843
Ming, Pen-Ming L., *765
Minick, Merlyn C., *702
Mirsky, Stanley, *226-227, *610-611
Mirura, Yasusada, 44-50
Mistry, S., *137
Mittra, B., *138
Mizel, Diane, *65
Mizuno, Yoshiatsu, 179-182, 901-904
Mobley, P. W., *517-518
Moody, A. J., 492-496
Moore, James M., *68
Moore, K. E., *68
Moorhouse, J. A., *533, *541, *848-849
Morales, Carlos, *435
Morgan, Carl R., *514-515
Mosses, Campbell, *65
Moss, James M., *541-542
Most, Sylvia, 222-224
Mougin, Janine, *435
Mouller, Sigfrid A., *368, *611
Munck, Ole, 323-326
Munive, Leopoldo, 130-132
Murchison, Lilian E., *849

*846 *368,

848

•915-

*518

°512-

-910,

N

Nabarro, J. D. N., *69, *439 Nabwangu, James, *140 Nakao, Kikiu, 44-50, *610 Naldjian, Santiago, *135 Narahara, H. T., *292, *516 Narduzzi, J. V., 507-510 Navarette, Victoriano N., 726-729 Neale, G., *368-369 Nechemias, Charles, *532 Nellen, M., *847 Neubronner, Peter, *291 Nibbe, Albert F., *545-546 Nielsen, A. V., *370 Nielsen, Robert L., *542 Niemeyer, Hermann, *917 Nabarro, J. D. N., *69, *439 Niemeyer, Hermann, *917 Nikkila, Esko A., *68 Ninomiya, Rikuo, 44-50 Nishikawa, Mitsuo, 709-713 Norman, Laurance L., 668-674 Nuttall, Frank Q., 5-8, *369

Oakley, Nigel, 219-222, °367 Oakley, Wilfrid, 219-222 Oberdisse, K., °438 O'Brien, John P., °138 O'Donovan, C. J., °536 O'Donovan, D. K., 790-797 Ogata, Yasuzo, 179-182 Ohlson, Margaret A., °64 Ohneda, Akira, °140 Ohta, Meisel, °520 Okinaka, Shizeo, 44-50, °610 Olita, Meisel, *520
Okinaka, Shigeo, 44-50, *610
Okun, Edward, *611
Okuno, Giichi, 709-713
O'Leary, James A., *436
Ooms, H. A., *915-916
Ooms, Henri, *763
Oppenheimer, Henry E., *542
O'Reilly, I. G., *227
Orskov, H., *437
Osawa, Gengo, *610
Östman, J., *914
O'Sullivan, John B., *369, 466-470, *528, *766, *849, *917-918
Otteman, Merlin G., *293
Owen, John A., Jr., 365
Oyama, Jiro, *703

Park, C. R., *433
Parker, Mary L., *226, *365, *844
Parrish, J. E., 734-739
Parry, D. G., *918
Partamian, Jean O., *293, *369
Patz, Arnall, *365, *437
Pearson, Olof H., *295, *546
Pedersen, Jørgen, *847
Pelkonen, Risto, *68
Penhos, J. C., 517, *530, *540, 740-748
Pérez, Norma, *917
Perkoff, Gerald T., 279-280
Perley, Michael, *867-874
Peters, Norma, *917
Perkoff, Gerald T., 279-280
Perley, Michael, *867-874
Peters, N., *68
Penhos, B. E. H., *703-704
Peters, N., *68
Pfeiffer, Ernst F., *291
Pictet, Raymond, *435
Pieri, Antonio, *293-294
Pietzykowa, Bogumila, 58-60
Pirart, J., *68-69
Piszkiewicz, D., *517-518
Platt, William T., *703
Plotkin, Gerald R., 565-570
Podolsky, Stephen, 222-224
Poffenbarger, Phillip L., *514, *542-543
Pogonowska, Magdalena J., *543
Porath, J., *764
Porte, Daniel, Jr., 143-148, 173-178, *434, *524, *543
Posner, Norman Ames, *611
Poucher, Russell, 838-841
Pouslen, J. E., 73-74
Powell, Elinor D. U., *543-544, 730-733
Powell, Richard C., *519-520
Powell, T., 269-275

Power, Lawrence, *69, 133-134, *228, *703 *703 Pozefsky, Thomas, *539 Poznanski, Rachel, *433-434 Poznanski, W. J., *544 Prahl, James W., 423-429 Prentice, Colin, *916 Pretlow, Thomas G., *701 Pringle, Dorothy Jutton, *611 Prior, I. A. M., *437 Provine, Harriet T., *769 Pruitt, Kenneth M., 342-345 Prystowsky, Harry, *370 Pupo, Armando Aguiar, 24-29 Pyke, D. A., *137

Rabajille, Eliana, *917 Rabb, G. B., 327-330 Rabinowitz, David, *516, *544, *848, 905-910, *917, *918 Rabkin, Mitchell T., *291-292, *543-544 Rafaelsen, Ole J., *437 Rasio, E. A., *138, *294, *369, *915-916 Rastogi, Krishna Sudha, 30-43, *515, 749-758 758 **292, *435, 586-596, *766, *918**

**eske-Nielsen, Edith, *437*
Reynolds, Marjorie Lavers, *611*
Ricketts, Henry T., *518-519, 880-888*
Rifkin, Harold, 222-224*
Rifkind, B. M., *294*
Ringsdorf, W. M., *228*
Rivera, E. M., *848*
Rizzo, Michelangelo, *293-294*
Roberts, Doris E., *525-526*
Roberts, J. B., *227*
Roberts, J. B., *227*
Roberts, Nancy, 336-341*
Robey, James M., *439*
Rodbell, Martin, *294*
Rodriguez, Ricardo R., 686-690*
Roe, J. H., *764*
Roginski, Edward E., *368*
Rogot, Eugene, *294*
Rogus, Ellen, *769*
Rojas, L., *532-533, *845-846*
Rondot, A. M., *137*
Root, Howard F., *228*
Root, Richard K., *915*
Roovete, Arved, *764, *848*
Rose, B. S., *437*
Rosen, Barbara J., *369-370*
Rosenau, Werner, 251-257*
Rosenbaum, Arthur L., *702* Rosenbaum, Arthur L., *702

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 February, 73-142 October, 709-774 June, 373-442 November, 775-854 March, 143-232 July, 443-554 December, 855-920 April, 233-302 August, 555-622

Rosenberg, Charles A., *550 Rosenberg, Philip, *67 Rosenbloom, Arlan L., *546-547 Ross, Herbert, 222-224 Rosselin, G., *139, *229 Rothstein, Aser, *704 Rubenstein, A. H., *513, *704 Ruderman, Neil, *545 Rull, Juan A., *67, *764-765 Rutherford, A., *69, *439 Ryan, Will G., *545-546

Sabeh, George, *845 Sailer, S., *437 Sak, Matthew F., 51-58, *702 Samaan, N., *294-295, *546 Samols, Ellis, *69, 855-866 Sanbar, Shafeek S., *369-370, *703 Sanchez-Medina, Mario, *531, *546 Sandhofer, F., *437 Sanbar, Shafeek S., "369-370, "703
Sanchez-Medina, Mario, "531, "546
Sandhofer, F., "437
Sarkozy, Eva, "529
Sarver, Margaret E., "845
Säve, Söderbergh J., "913
Sawrey, K. R., "229
Saydyk, Theodore G., "658
Scarpelli, Dante G., 262-268
Scarpelli, Paolo T., "293-294
Schafer, Michael E., "844
Schalch, Don S., 365, "527, 766-767
Schane, H. Philip, "437-438
Scharff, R., "139
Schilling, S., 173-178
Schilling, W. H., "438
Schless, Guy Lacy, "438
Schlichtkrull, J., "370
Schlierf, Guenter, "527, "538
Schmidt, F. L., "534
Schmidt, Philip, "842
Schmidt, Philip, "842
Schmidt, M., "138
Schnaider, José, 24-29
Schnute, Richard B., "519-520
Schoeller, K. L., "140
Schöffling, Karl, "291
Schroeder, Henry A., "368
Schulz, M., "434-435
Schulze-Sölde, R., "433
Schwartz, Melvin J., "226-227, "610-611
Schwartz, Robert, "917
Schwartz, Robert, "917
Schwartz, Theodore B., 233-250, "545-546
Schwarz, K., "433, "916-917 Schwarz, K., °433, °916-917 Scott, D. J., °367 Scow, Robert O., °135-136, °291, °609-610 610 Scuderi, S., °540 Searle, G. L., 173-178, °520 Settel, H. C., °513, 694-696 Settel, Leroy, °532 Seidman, Frances, °538-539 Sells, M. E., °844 Sells, Robert, °137 Seltzer, Holbrooke S., *523 Setyaadmadja, A. T. S. H., *228 Sevitt, L. H., *435

Seyfert, Willis, *515-516
Shaper, A. G., *849
Shapiro, Fred L., *703
Sharkey, Thomas P., *918
Sharpe, Alton R., Jr., *138
Shelburne, S. A., Jr., 411-418
Shelkrot, Joel W., 507-510, *845
Sherman, Lawrence, 149-159, *546-547
Shinji, Yoshitake, 709-713
Shipp, Joseph C., *295
Shirai, Takeshi, *547
Shklar, Gerald, *531
Shoemaker, William C., *226, *434
Shugarman, Richard G., *365
Siess, E., *139-140, *438
Silverstone, Felix A., *611
Simons, E. L., 734-739
Sims, Ethan A. H., *547
Singh, V. N., *438-439
Skipper, E. W., *67
Skillman, Thomas G., *525
Skovborg, F., *370
Slone, Dennis, *703
Slonevsky, Lillian, 400-405
Smith, A. W. M., *295
Smith, Henry T., 703
Smith, Henry T., 703
Smith, Russell E., *766
Sneyd, J. G. T., *433
Sodero, E., *517
Soeldner, J. Stuart, *140, *294, *518, *586-596, *703, *766, *917
Sokal, Joseph E., *439
Söling, H. D., *767
Somlo, Z., *228
Sonenberg, Martin, *134
Sönksen, P. H., *69, *439
Soscia, John L., *65
Sparks, Lowell L., *136
Spellacy, W. N., *140
Spergel, Gabriel, 406-410, 759, *841, *842
Spiro, Robert G., *512
Spring, Maxwell, *547
Schlar J. L. *1800 Spergel, Gabriel, 406-410, 759, *841, *842
Spiro, Robert G., *512
Spring, Maxwell, *547
Stahlgren, LeRoy H., *293
Stamp, T. C. B., *70
Stanten, Arthur, *138
Staquet, Maurice, *140, *295
Stauffacher, Werner, *139, *435
Steen Olsen, T., *437
Steenrod, William J., Jr., 423-429
Stein, Jay H., *439, *528
Stein, Jay H., *439, *528
Steinberg, Arthur G., *527-528
Steinberg, Terry, 838-841
Steinke, Jurgen, *140, 586-596, *703, *766, *917
Stener, B., *134
Stenger, Vincent, *370
Sterky, G. C. G., *7703-704, *844
Stern, Alan, *842
Stewart, A. G., *548
Stewart, R. D. H., *140
Stimmler, Leo, 1-4, *848
Stobbe, H., *847
Stone, Daniel B., \$14-318

Streeten, David H. P., *535, *539-540 Strich, Sabina J., *843 Struck, E., *139-140 Subauste, Carlos, *70 Sunder, J. H., *70 Sussman, Karl E., 1-4, *521, *767 Sutherland, Earl W., *433 Sutter, B. C. J., *138 Swan, Danna C., *439 Swan, Danna C., *439 Swift, Charles, *538-539 Szabo, A. J., *548 Szabo, O. *540-541 Szabo, A. J., *548 Szabo, O., *540-541 Szücs, Susanne, *228

Vecch Vega, Vesen Vikto Viktor Viljan Volk, Von I Vong Vrba,

Wagle

Waitz Wajch Wales

Wall, Walla

Warn Warre Watar Watki Weath Webe Weese

Wegie Weinh Welbo Welbo Weller Wellm Wells, Welsh Wendt Werth

Tarrant, M. E., 346-350
Tashjian, Anahid, *228
Taylor, J., *137
Taylor, K. W., *435, *918
Tchobroutsky, G., *139, *229
Teinzer, A., *438, *139-140
Telfer, Nancy, *768
Tenney, Benjamin O., 466-470, *917-918
Thomas, P. K., *295
Thorell, Jan I., *768
Thornton, Baymond, *370 Thorell, Jan I., **768
Thorell, Jan I., **768
Thornton, Raymond, **370
Tilak, Manohar A., **367
Timmer, Richard F., **521, **767
Tirador, Dean F., **439
Tittle, Robert C., 212-219
Tometsko, Andrew M., **367
Toreson, Wilfred E., 579-585
Torres, Isabel H., 726-729
Traisman, H. S., *411-418
Tranquada, Robert E., **548, 807-809
Trap-Jensen, Jens, 323-326
Travis, Randall H., 307-313
Triplett, R., **528
Tsujii, Tsutomu, 709-713
Tucker, Donald R., **64
Tucker, W. Randolph, 233-250, **545-546
Tullis, James L., **369
Tulloch, C. G., **66
Turner, D. S., **293, **370
Turner, Paul C., **548
Tustison, Winston A., 775-777 Tustison, Winston A., 775-777 Tzagournis, Manuel, *526, *549

Unger, Roger H., 500-506, *522-523, *532-533, 845-846 Urgoiti, Enrique J., *291

Van Itallie, Theodore B., 723-725 van Steveninck, Johnny, *704 Vaughn, Gary D., *521, *767 Vavra, Helen M., *366, *541 Vecchi, Adalberto, *67 Vecchio, D., *918

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

Stone, Daniel B., 314-318 Stowers, John M., *228-229 Stratman, Stanley, *295

September, 623-708 January, 1-72 May, 303-372 October, 709-774 February, 73-142 June, 373-442 November, 775-854 March, 143-232 July, 443-554 December, 855-920 April, 233-302 August, 555-622

Vecchio, Thomas J., °65 Vega, E. G., °528 Vesenne, Marja-Riitta, °68 Viktora, Joseph, °295, °550 Viktora, J. K., °550 Viljanen, Veikko, °916 Volk, Bruno W., °549 Von Eueler, Ulf S., °848 Vongaraya, Nori, 303-306 Vrba, R., °768

9-540

917-918

809

45-546

22-523,

W

Wagle, S. R., 19-23, °549-550
Waitzkin, Leo, 97-104, 164-172, °550
Waichenberg, Bernardo L., 24-29
Wales, J. K., °550, °551
Wall, Mary, °227-228
Wallace, A. L. C., °439
Warner, Nancy E., 597-603
Warren, James C., °914
Watanabe, Gen-ichi, 194-204
Watkins, Julia D., 525-526
Weatherburn, M. W., 127-129
Weber, Herbert, °524-525
Weese, Winston H., °702-703
Wegienka, Laurence C., 571-578
Weinhouse, Sidney, °226
Welborn, T. A., °704
Welbourn, R. B., °294-295
Weller, Charles, °611
Wellmann, Klaus F., °549
Wells, M. V., °67, °435-436
Welsh, George W., III, °547
Wendt, F., °847
Wertheimer, H. E., °434, °701 Wertheimer, H. E., *434, *701

Wesley, M. E., *516 West, Kelly M., 9-18, *439, *528, *768-769 Westey, Mr. E., 310
West, Kelly M., 9-18, *439, *528, *768-769
West, R. O., *229
Wheaton, E. A., 357-359
Wherry, Frances E., *769
Whichelow, Margaret J., *134-135, *855
White, J. J., *532-533, *845-846
White, Priscilla, *70
White, R., *517
Whitehouse, Fred W., *918
Whiney, J. E., *365
Wick, A. N., *517-518
Wieland, O., *139-140, *438
Wikman, John H., *769
Wilkerson, Hugh L. C., *849
Williams, Cicely D., *769
Williams, Cicely D., *769
Williams, R. F., *518, *528
Williams, Robert H., 143-148, *434, *514, *515, *542-543, 623-654, *845
Williams, T. Franklin, *525-526
Williams, T. Franklin, *525-526
Williamson, Joseph R., 183-187, 188-193
Williams, D. L., *229
Wilson, R. B., 258-261
Wilson, R. B., *512-513
Winegrad, Albert I., *918
Winkelmann, R. K., *368, *611
Woeber, Kenneth A., *70, *769
Wohltmann, Hulda J., *516
Wolfe, Ava J., 894-900
Wolff, Frederick, *140, *295, 319-322
Wolff, F. W., *551
Wolfson, Jerome H., 276-277

Wood, W. Barry, Jr., *915 Wood, Francis C., Jr., *434, *515 Wool, I. G., *139 Wray, H. Linton, *918 Wright, Agnes, 691-694 Wright, Peter H., *521, 668-674 Wu, C. H., *517, 740-748 Wynn, V., *70

Y

Yabo, Roberto, *295 Yalow, Rosalyn S., 875-879 Yamagata, Shoichi, *140 Yamauchi, Yuichi, *140 Yen, Samuel S. C., *295 Yaraanian, George, *531 Yerganian, George, *531 Yodaiken, R. E., *513 Yoshinaga, Tetsuo, 709-713 Young, J. D., *702 Yu, Shiu Yeh, 812-822

Z


Zaharko, Daniel S., *136, 336-341, 680-885 Zahnd, Gaston R., °551, °918 Zalut, Clyde, °367 Zammit Maempel, J. V., °295 Zampa, Gian Angelo, °67 Zeytinoglu, Ibrahim, °551 Zierler, Kenneth L., °544, *769 Zinneman, Horace H., 5-8 Zorilla, Eduardo, 419-422

DIABETES: VOLUME 15 (1966) PAGE NUMBERS BY ISSUE

January, 1-72 May, 303-372 September, 623-708 February, 73-142 October, 709-774 June, 373-442 March, 143-232 July, 443-554 November, 775-854 April, 233-302 August, 555-622 December, 855-920



Memoranda





American Diabetes Association, Inc. 18 East 48th Street New York, N. Y. 10017

